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1 Introduction 
 
1 Introduction 
Hepatitis C virus (HCV) infection causes approximately 40 % of chronic liver 
diseases worldwide and is considered as a serious public-health problem. According 
to the estimates of the World Health Organization (2010), over 170 million people are 
infected with HCV, of whom 60 to 80 % develop chronic hepatitis, leading to cirrhosis 
in 10 to 20 % and to hepatocellular carcinoma (HCC) in 1 to 5 % of infected 
individuals. In the western industrial countries, HCV is the major cause of liver 
transplantations (Brown, 2005). Currently, a combination therapy with interferon- 
(IFN-) supplemented with the nucleoside analog ribavirin is used for treatment of 
chronic HCV infection but a sustained virological response is achieved only in about 
50 to 80 % of patients (Zeuzem, 2004). A response rate depends on virus genotype, 
so that a sustained response is achieved in 88 % of cases of genotype 2, whereas 
for genotypes 1, 4, 5 and 6 in only 48 % of cases a sustained response is observed 
(Poynard et al., 2003). These data emphasize the need for new 
prophylactic/therapeutic approaches that would prevent spread of HCV and would 
provide more efficient antiviral therapy of individuals suffering from a chronic hepatitis 
C. The progress in development of HCV vaccine and new therapeutic approaches 
will undoubtedly depend on our knowledge of biology of HCV and characteristics of 
its interaction with the infected host. In the current section of this thesis an attempt is 
made to summarise a large bulk of information on molecular biology of HCV, 
including organization of its genome, mechanisms of its replication, characteristics of 
viral proteins, and peculiarities of antiviral immune responses.  
1.1 The HCV Virus 
Morphology of the HCV  
HCV is a coated ecosaedric virus whose diameter is about 50 to 70 nm (Kaito et al., 
1994; Li et al., 1995). HCV has been classified as the only member of the 
Hepacivirus genus and belongs to the Flaviviridae family. Due to the similarity with 
other Flaviviridae viruses, HCV contains an envelope consisting of two envelope 
proteins E1 and E2. These proteins enclose the spheric nucleocapsid, which is 
composed of the core proteins and in turn contains the viral RNA (Penin, 2003). 
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 The HCV genome 
The HCV genome is a single-stranded RNA molecule of positive polarity 
approximately 9.6 kb in length. It contains a single open reading frame (ORF) of 
approximately 9 kb that encodes a polyprotein of 3000 amino acids (a.a.). The ORF 
is flanked at both ends by untranslated regions (UTR), which are the most conserved 
regions of the genome (Cocquerel et al., 2006). The 5’UTR consists of 342 
nucleotides (nt) and contains an internal ribosomal entry side (IRES), which mediates 
the translation of the polyproteins (Tsukiyama-Kohara et al., 1992). Downstream of 
the coding region another untranslated region of approximately 200 nucleotides 
(3’UTR) is located, which can be divided into 3 parts: a variable region (ca. 40 nt), a 
poly-uracil track of a variable length (20 to 90 nt), and a highly conserved region  
(98 nt), which is essential for replication (Cheng et al., 1999; Kolykhalov et al., 1996; 
Tanaka et al., 1996; Yamada et al., 1996).The polyprotein consisting of 
approximately 3000 a.a. is cleaved by viral and host enzymes into 10 polypeptides: 
core, envelope 1 (E1), envelope 2 (E2), p7, non-structural protein 2 (NS2), non-
structural protein 3 (NS3), non-structural protein 4A and 4B (NS4A and NS4B), and 
non-structural proteins 5A and 5B (NS5A and NS5B) (Fig.1.1.). 
HCV can be classified on the basis of the dissimilarity of nucleotide sequences into 
major genetic groups or genotypes. There are 7 HCV genotypes. Most of them 
consist of several subgroups or subtypes. Due to a high selective immune pressure, 
virus circulated in the infected host consist of a large population of closely related but 
still distinct genetic variants or quasispecies. The causes of a high sequence diversity 
of HCV are a high rate of nt misincorporation by virus-encoded error-prone RNA 
polymerase (NS5B protein) and a large size of virus RNA population. The error rates 
of approximately 1 per 10.000 copied base pairs combined with a high rate of virus 
production of up to 1012 virions per day (Neumann et al., 1998; Simmonds, 2004) 
lead to appearance of an extremely diverse population of virus genetic variants, 
which are subjected to an immune selection driven by host. 
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Fig.1.1. Genomic organization of the HCV genome 
Cleavage sites of the cellular proteases (green arrows), the NS2 proteases (blue arrow) and the 
NS3/4A protease-complex (orange arrows) are indicated. 
 
HCV encoding proteins 
The ORF of HCV encodes a polyprotein of 3022 a.a.. The polyprotein is co- and post 
translationally cleaved by viral and host-cell proteases into 10 functional subunits. 
The structural proteins are located in the N-terminal part, whereas the non-structural 
proteins are located at the C terminal part of the polyprotein. Core, E1 and E2 are the 
major constituents of virions. 
Core, as the first structural protein is located directly at the N-terminus. It forms the 
nucleocapsid which encloses and interacts probably the genomic RNA (Baumert et 
al., 1998). This protein seems to play a role in different cellular signaling transduction 
cascades and in the oncogenesis (Chang et al., 1998; Matsumoto et al., 1997). 
The HCV proteins E1 and E2 are the membrane-associated glycoproteins, forming 
an integral part of the HCV virion envelope. The proteins are targeted to the 
endoplasmatic reticulum (ER), where they are cleaved from the viral polyprotein by a 
host signal peptidase cleavage (Dubuisson et al., 2002). They are type-I 
transmembrane proteins of about 35 kilo Dalton (kd) and 70 kd (746 aa), 
respectively, with a large N-terminal ectodomain and a C-terminal transmembrane 
domain, and they assemble as noncovalent heterodimers (Deleersnyder et al., 1997). 
Both E1 and E2 transmembrane domains are composed of two short stretches of 
hydrophobic a.a. separated by short polar segment containing fully conserved 
charged residues (Cocquerel et al., 2000), whereas the second hydrophobic stretch 
acts as an internal signal peptide for the downstream protein (Cocquerel et al., 2002). 
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 Before signal-sequence cleavage, the E1 and E2 adopt a hairpin structure and after 
cleavage by a host signal peptidase the signal-like sequence is re-oriented towards 
the cytosol, which, in turn, leads to a transmembrane passage (Cocquerel et al., 
2001). The deletion of the C-terminal hydrophobic regions of the proteins leads to 
their secretion (Michalak et al., 1997), suggesting that these regions are involved in 
membrane anchoring. E1 and E2 can also form heterodimers of both covalent 
(disulfide-bonded) and non-covalent types (Choukhi et al., 1999).  
The E2 glycoprotein contains a hypervariable region I (HVRI), in which, presumably, 
one of the major neutralization epitopes is located (Farci et al., 1996). High variability 
of HVRI during infection is considered as a major mechanism that allows the virus to 
avoid the host humoral immune response (Farci et al., 2000). Experimental deletion 
of the E2 HVRI results in persistent (albeit low-level) viremia, which suggests that this 
region is not essential for viral replication, but that its disruption might lead to 
attenuation of the viral infection (Forns et al., 2000), which might be explained by its 
involvement in virus entry (Bartosch et al., 2003c; Callens et al., 2005). The E2 
glycoprotein contains another hypervariable region, HVR2, which has been described 
in HCV genotype 1 strains (Kato et al., 2001) and includes a stretch of 7 a.a. 
(position 91-97) which demonstrate a high level of sequence diversity. It is assumed, 
that HVRI modulates a binding of E2 to the host receptor CD81 (Roccasecca et al., 
2003; Sklan et al., 2009; Zeisel & Baumert, 2009). 
HCV envelope glycoproteins are retained in the ER (Deleersnyder et al., 1997; 
Dubuisson et al., 1994), whereas ER retention signals are present in the 
transmembrane domains of E1 and E2 (Cocquerel et al., 1999; Cocquerel et al., 
1998). The charged residues of the transmembrane domains of E1 (Lys) and E2 
(Asp and Arg) play the key role in the ER retention of these glycoproteins (Cocquerel 
et al., 2000). Furthermore, it was shown, that the transmembrane domains also have 
an important role in the assembly of E1/E2 heterodimer (Op De Beeck et al., 2000). 
Although the E1/E2 heterodimer is mainly retained in the ER, HCV glycoproteins can 
also be detected at the plasma membrane. Importantly, the retention of E1/E2 in the 
ER has been confirmed in HCV cell culture (HCVcc) - infected cells (Rouille et al., 
2006). 
The ectodomains of HCV envelope proteins E1 and E2 are highly modified by N-
linked glycans, whereas they posses up to 6 and 11 potential glycosylation sites, 
correspondingly, and most of them are well conserved (Dubuisson, 2007; Goffard & 
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 Dubuisson, 2003). In the early secretory pathway, the glycans play an important role 
in protein folding, quality control and certain sorting events. Viral envelope proteins 
usually contain N-linked glycans that can play a major role in their folding, in their 
entry functions or in modulating the immune response (Ohuchi et al., 1997a; Ohuchi 
et al., 1997b). Sequence analyses suggest that N-glycosylation sites in the E1 are 
strongly conserved among HCV genotypes (Goffard & Dubuisson, 2003). For E2 a 
global sequence analysis indicate that 9 of 11 sites are strongly conserved. The two 
remaining sites show conservation levels of 75 % and 89 %, respectively (Goffard & 
Dubuisson, 2003; Lavie et al., 2007). Studies with HCVpp showed that the HCV 
envelope protein glycosylation is dependent on fewer than 14 a.a. ahead of E1 and 
12 a.a. ahead of E2 (Bian et al., 2009). It is worth noting, that some glycans have 
been shown to play a role in HCV glycoprotein folding or in virus entry (Dubuisson, 
2007; Goffard et al., 2005). The most recent data obtained using the HCVcc system 
confirm that the glycans associated with HCV envelope glycoproteins play an 
important role at different steps of viral life cycle especially in HCV assembly and/or 
infectivity. It was also demonstrated that at least five glycans on E2 strongly reduce 
the sensitivity of HCVcc to antibody neutralization. Four of these sites surround the 
CD81 binding domain (Helle et al.). 
HCV envelope glycoproteins have been shown to assemble as a concovalent E1/E2 
heterodimer (Deleersnyder et al., 1997). However, in heterologous expression 
systems, HCV envelope glycoproteins have a tendency to form misfolded aggregates 
stabilized by disulfide bonds. Therefore, analyses of E1/E2 heterodimer with 
conformation-sensitive antibodies are necessary to distinguish noncovalent 
heterodimers from misfolded complexes (Cocquerel et al., 2003b; Deleersnyder et 
al., 1997). Analysis of the formation of conformation-dependent epitopes 
demonstrated that the process of folding of HCV envelope glycoproteins is a very 
slow one (Brazzoli et al., 2005; Dubuisson & Rice, 1996). Analysis of the disulfide 
bonds formation in attempt to establish a tertiary organization of the E2 molecule 
revealed that the E2 ectodomain consists of 28 % ß-sheets (Krey et al.). The folding 
of E1 has been shown to be dependent on the co-expression of E2 (Michalak et al., 
1997) and vice versa (Brazzoli et al., 2005; Cocquerel et al., 2003a).  
C-terminal to the E2 the p7 membrane protein is located. It was assigned to the 
viroporins group and is essential for formation of ion channels for the last steps of 
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 virus replication (Carrere-Kremer et al., 2002). Moreover, p7 is required for assembly 
and release of infectious particles (Jones et al., 2007; Sakai et al., 2003). 
The non-structural proteins NS2, NS3, NS4A, NS4B, NS5A und NS5B have different 
functions during the process of viral Ribunucleic acid (RNA) - replication and 
proteolytic protein processing (Lohmann et al., 1999). NS2 is acting as membrane 
protein, which is not essential for HCV RNA replication (Blight et al., 2000; Lohmann 
et al., 1999). The NS2/NS3 protease cleaves the NS2/NS3 junction. Additionally, 
NS2 domain is further required for the production of infectious virus (Jirasko et al., 
2008). The multifunctional NS3 protein consists of a N-terminal serine protease, 
which catalyzes the processing of all other nonstructural proteins within the C-
terminal part of the precursor polyprotein. The C-terminal part of the NS3 protein 
contains the RNA helicase/nucleoside triphosphate hydrolase (NTPase) domain that 
is essential for translation and RNA-replication (Bartenschlager et al., 1993). 
Formation of a heterodimer NS3-NS4A enhances the activity of the protease 
(Bartenschlager et al., 1994). This complex is essential for processing of all proteins 
located C-terminal of NS3. Recent studies demonstrated that the NS3/NS4A also 
targets some host proteins that are involved as signaling intermediates in virus-
induced production of Interferon- ß (IFN-ß) (Li et al. 2005). The NS4A protein is a 
membrane protein forming the membrane structure and supporting RNA replication 
(Egger et al., 2002). The NS4B protein appears as punctuate foci at the ER 
membrane and consists of four central transmembrane domains with N- and  
C-termini located in the cytoplasm of the host cell (Lundin et al., 2003). Due to the 
important function as a component of the replicase complex, NS4B, is thought to 
create sites for genome synthesis and, as has recently been further suggested, 
contributes to the processes engaged in virus assembly and release (Jones et al., 
2009). The membrane associated NS5A protein is essential for HCV genome 
replication through its interaction with viral replication complex and several host cell 
factors (Evans et al., 2004). It was shown, that the interaction of NS5A with NS5B is 
required for the maintenance of the subgenomic replicon in transfected cells (Shirota 
et al., 2002). NS5B, as a membrane associated protein acts as a viral RNA-
dependent RNA polymerase (Bartenschlager et al., 2004; Behrens et al., 1996). The 
RNA polymerase activity can presumably be modulated by interaction of NS5B with 
viral proteins NS3 and NS5A.  
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 Additionally, within the core region, an alternative reading frame is present (Branch et 
al. 2005). The encoded protein received the name of alternative frame protein 
(ARFP) or frame shift protein (F protein). It comprises of up to 160 a.a.. Sequencing 
of the in vitro labeled ARFP protein indicated that the frameshift junction is likely to 
occur at codons 9 to 11 of the core protein sequence (Xu et al. 2001). The function of 
this protein in the lifecycle remains unclear. 
1.2 Model systems of HCV infection 
1.2.1 in vivo models 
The only animal species, which supports HCV replication and shows a similar course 
of disease as human beings, is chimpanzee. This animal model seems to be ideal to 
get new insights into the progression of the HCV infection and to gain new 
perceptions of the immune response in acutely infected and chronically infected 
animals. An obvious advantage of working with chimpanzees is the utilization of the 
same reagents and methods as used for human beings. Nevertheless, working with 
this animal model also reveals disadvantages like high maintenance cost, scarcity 
and ethical considerations. Multiple attempts were made to develop a more suitable 
small animal model for HCV. Thus, some attention was drawn to the tupaias 
(T.belangeri chinensis) (Xie et al., 1998), a species already shown to be susceptible 
to infection with hepatitis B virus (Walter et al., 1996; Yan et al., 1996). However, only 
one quarter of the animals became infected with HCV and develope in most cases 
only transient viremia with low virus titres. Another approach was the HCV infection 
of a SCID mouse grafted with human hepatocytes (Mercer et al., 2001). Although the 
SCID mouse provide an opportunity to study some characteristics of HCV infection, 
this model also has some disadvantages, including requirement for a special 
expertise for establishment and handling, and a high mortality rate of animals. 
1.2.2 in vitro models 
To study the complexicity of the HCV life cycle, in vitro models had to be invented. At 
the beginning scientists developed systems that led to the overexpression of HCV 
proteins in cell cultures (Macdonald & Harris, 2004). Subsequent development of a 
subgenomic and, few years later, of a full genomic HCV replicons provided us with 
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 new opportunities to study different aspects of HCV replication and HCV replicons 
were used with a lot of success in many laboratories worldwide (Lohmann et al., 
1999) (Blight et al., 2002; Lohmann et al., 2003). (Blight et al., 2003) (Kato, Date et 
al. 2003) (Pietschmann et al. 2002). Unfortunately, all generated replicons despite 
relatively high rates of HCV RNA replication did not produce infectious virions. The 
breakthrough occurred only after preparation of the replicon on the basis of the virus 
strain isolated in Japan from a patient with fulminant hepatitis (Kato et al., 2003). The 
generated JFH-1 replicon was not only able to replicate in Huh7 cells without any 
adaptive mutations but also produced the mature infectious virus particles. 
Experiments with this clone in several laboratories led to the development of cell 
culture systems that allowed for a relatively efficient replication of HCV in vitro 
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005). The virus produced 
by these systems was referred to as a cell culture derived virus or HCVcc. The 
developed systems were based on transfection of the human hepatoma cell lines 
Huh7.5 or Huh7.5.1 with genomic HCV RNA of genotype 2a JFH1 strain. In order to 
allow comparative studies between different HCV strains, chimeric genomes 
encoding the structural proteins from different genotypes (e.g. from genotype  
1a strain H77) and the non-structural proteins from the JFH1 strain have been made 
(Lavie et al., 2007; Pietschmann et al., 2006). The viruses produced in cells 
transfected with these chimeric RNAs were infectious for naïve cells, for 
chimpanzees and for immunodeficient mice transplanted with human hepatocytes 
(Lindenbach et al., 2006; Wakita et al., 2005). It was also shown that HCVcc could be 
efficiently neutralized by anti-HCV antibodies derived from human sera (Wakita et al., 
2005), as well as by polyclonal anti-envelope antibodies (Pietschmann et al., 2006). 
Thus, the HCVcc system provides an exellent opportunity to study the complete HCV 
life cycle. 
In parallel to the development of HCV replicon-based systems several other models 
suitable for studies of some stages of HCV replicative cycle were proposed. The 
most successful of these systems was based on pseudotyping of particles produced 
by other viruses, including vesicular stomatitis virus (VSV) or retroviruses, with HCV 
E1 and E2 glycoprotein (Lagging et al., 1998; Matsuura et al., 2001) (Bartosch et al., 
2003b; Drummer et al., 2003; Lavie et al., 2007). In most of the cases, the murine 
leukemia virus (MLV) of human immunodeficiency virus (HIV) vectors was used. 
Retroviruses are known to be able to incorporate into their envelope a variety of 
cellular and viral glycoproteins (Ott, 1997). Furthermore, it is known that they can 
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 easily package and deliver into the transfected cells different genetic markers  
(Negre et al., 2002). These properties are exploited to produce viral pseudoparticles 
expressing HCV E1/E2 at their surface and packaging a reporter gene that allows the 
monitoring of viral infection. The HCV pseudoparticles (HCVpp) are produced by 
transfection of human embryo kidney 293T cells with two or three expression vectors 
encoding the HCV E1/E2 proteins, the retroviral gag/pol proteins, and a packaging-
competent retrovirus-derived genome containing a marker gene like the green 
fluorescent gene (GFP) or the firefly luciferase gene (Fig.1.2). The produced HCVpp 
are infectious for cell lines of hepatocyte origin, principally for Huh7.5 cells and their 
derivatives as well as for human primary hepatocytes (Bartosch et al., 2003b; Hsu et 
al., 2003). Nowadays, the HCV pseudoparticles model (HCVpp) is widely used for 
analysis of the mechanisms of HCV entry and studies of HCV-specific humoral 
immune responses. 
 
Fig.1.2. Production of HCV pseudopaticles (HCVpp) (Lavie et al., 2007) 
293T cells are transfected with three expression vectors. The first vector encodes retroviral Gag and 
Pol protein. Gag proteins are responsible for particle budding at the plasma membrane and RNA 
encapsidation via recognition of the specific retroviral encapsidation sequence (). The second vector 
harbors a  sequence for encapsidation and encodes a reporter protein (Luciferase). This vector also 
contains retroviral sequences that are necessary for the reverse transcription of genomic RNA into 
proviral DNA by retroviral protein Pol encoded by the first vector. The third vector encodes HCV 
envelope glycoproteins, which are responsible for the cell tropism and fusion of HCVpp with the target 
cell membrane (Lavie et al., 2007).  
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 1.3 The replication cycle 
The HCV replication cycle starts with the process of viral entry into the host cell 
(Fig.1.3.). This complex multistep process is still not clear but it is known that the two 
envelope proteins E1 and E2 play the major role in virus entry (Bartosch & Cosset, 
2006; Cocquerel et al., 2006). HCV enters cells by clathrin-mediated endocytosis 
(Blanchard et al., 2006). A number of cellular receptors and co-receptors of HCV 
have been identified. They include glycosaminoglycans, the Low density lipoprotein 
(LDL) receptor, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
Non-integrin (DC-SIGN), and liver/lymph node-specific intracellular adhesion 
molecules-3 grabbing non-integrin (L-SIGN), CD81, Scavenger receptor class B 
member 1 (SR-BI), claudin-1 and occludin-1 (Sabahi, 2009). Recent studies suggest 
that within the endosome, the low pH environment triggers the fusion process of the 
virus with the endosomal membrane and the introduction of the HCV genome into the 
cytoplasm (Lavillette et al., 2006). After the process of entry, RNA is released into the 
cytoplasm and serves directly as mRNA for the synthesis of viral proteins. Following 
the polyprotein processing, the proteins retain at the membrane of the ER. The 
expressed HCV proteins induce intracellular membrane alterations. The generated 
replication-complex is bound to the altered cell membrane (Moradpour et al., 2003). 
The RNA with positive polarity serves as matrice for the synthesis of RNA of negative 
polarity, which is used afterwards for the synthesis of positive strands of RNA. The 
new RNA with positive polarity is consequently used for synthesis of negative strands 
of RNA, which is used for protein expression or for virion packaging. The mature 
virion is thought to possess a nucleocapsid and outer envelope composed of a lipid 
membrane and envelope proteins. Virion assembly presumably begins with the 
interaction of capsid proteins and genomic RNA to form a nucleocapsid, which 
acquires an envelope and the matured virion is then secreted by following the 
classical secretory pathway. 
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Fig.1.3. Schematic representation of the major steps of HCV replication cycle  
(Dubuisson et al., 2007) 
HCV binds to the receptor complex at the cell surface, which leads to endocytosis of the particle. 
Fusion of viral envelope and endosomal membrane leads to the release of the HCV genome into the 
cytosol. Positive stranded RNA is directly translated and all viral proteins are simultaneously 
produced. Expression of HCV proteins induces intracellular membrane alterations (membranous web), 
where RNA replication takes place. Accumulation of HCV genomic RNA and the structural proteins 
leads to the assembly of a nucleocapsid, which acquires its envelope within an intracellular 
compartment. The viral particle is then secreted by following the secretory pathway. 
1.4 The role of envelope proteins during HCV entry 
Binding and entry of HCV is believed to be a complex multistep process involving the 
HCV envelope glycoproteins E1 and E2, as well as several attachment and entry 
factors like CD81, SR-BI, members of the claudin family and occludin. CD81 was 
recognized early as an entry receptor for HCV after the experiments, in which a 
soluble form of HCV glycoprotein E2 was used (Pileri et al., 1998). The tetraspanin 
CD81 is a widely expressed 25-kd cell surface protein that is involved in pleiotropic 
activities such as cell adhesion, motility, metastasis, cell activation, and signal 
transduction (Levy et al., 1998). It is a member of the tetraspanin family type III 
proteins and contains two extracellular loops and one short intracellular loop. Due to 
the lack of an in vitro infectious system, early studies identified that the long 
extracellular loop (LEL) is necessary for soluble E2 binding (Petracca et al., 2000). 
Anti-CD81 antibodies and soluble recombinant forms of the LEL have been shown to 
inhibit HCVpp and HCVcc entry into Huh7 hepatoma cells and hepatocytes (Bartosch 
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 et al., 2003b; Hsu et al., 2003). Further experiment demonstrating that transduction 
of HepG2 and HH29 human hepatoma cells lacking CD81, to express CD81 
rendered them permissive for HCV infection (Flint et al., 2006). Furthermore, small 
interfering RNA (siRNA) silencing of CD81 showed a reduction of viral infection  
(Flint et al., 2006; Lindenbach et al., 2005). Recent studies using the HCVpp and 
HCVcc model system provided evidence that inhibition of viral entry by anti-CD81 
antibodies appears to occur at a post-binding step of HCV (Koutsoudakis et al., 
2006). These findings indicate that CD81 plays an important role as an HCV cell 
entry receptor at a post binding step during the initiation of infection (Barth et al., 
2006). Studies analyzing the E2-CD81 interaction and identification of epitopes 
recognized by antibodies that inhibit these interactions propose that the CD81-
binding region contains residues critical for CD81 binding, which were detected via 
site-directed mutagenesis (Owsianka et al., 2006).  
SR-BI was identified as an 82-kd E2 binding protein by demonstration that soluble  
E2 (sE2) bounds to CD81-negative HepG2 cells by means of SR-BI (Scarselli et al., 
2002). SR-BI is highly expressed in liver and steroidogenic tissues (Krieger, 2001), 
as well as in human monocyte-derived dendritic cells (Yamada et al., 2005). It is 
involved in trafficking bidirectional cholesterol transport into hepatocytes by uptake of 
high-density lipoproteins (HDL) and low-density lipoproteins (LDL) into endosomes. 
HDL enhances HCV entry, a process which depends on the lipid transfer function of 
SR-BI (Voisset et al., 2005). Different SR-BI ligands have been shown to influence 
infection, acting to enhance, like HDL (Dreux et al., 2006), or inhibit, like oxidized 
LDL (Cai et al., 2007; Lavie et al., 2006), viral entry. Kinetics of inhibition with  
anti-SR-BI antibodies suggest a concomitant acting of SR-BI with CD81 (Zeisel et al., 
2007b). It has been shown, that antibodies directed against cell surface-expressed 
SR-BI inhibits HCV-like particles binding to primary hepatocytes (Barth et al., 2005) 
as well as HCVpp (Bartosch et al., 2003c) and HCVcc entry (Bartosch et al., 2003c). 
Another host cell molecule, a tight junction protein Claudin-1 (CLDN1), was recently 
identified to be of importance for HCV entry (Evans et al., 2007). Tight junctions are 
continuous intercellular contacts located at the apical poles of lateral cell membranes 
(Stevenson & Keon, 1998). The expression of CLDN-1 in several cell lines allowed 
for HCVpp and HCVcc entry. The siRNA silencing of CLDN-1 expression in 
permissive hepatoma cells reduced HCV infection. Furthermore, antibody blocking 
studies, in which the tagged versions of CLDN-1 were used, showed that the first 
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 extracellular loop is an essential co-receptor molecule during late stage of the HCV 
entry process (Evans et al., 2007). Recently, Claudin-6 and Claudin-9 were identified 
acting as other HCV co-receptors (Zheng et al., 2007). Anti-CLDN-1 antibodies have 
shown an inhibition of binding of envelope glycoprotein E2 to HCV permissive cell 
lines in the absence of detectable CLDN1-E2 interaction. These antibodies also 
neutralized the HCV infectivity by reducing E2 association with the cell surface and 
disrupting CD81-CLDN1 interactions (Krieger et al.). The most recent data confirmed 
that the interaction of Claudin with CD81 seems to be essential in HCV infection 
(Harris et al.) 
Glycosaminoglycan chains on cell surface proteoglycans serve usually as attachment 
sites for the binding of number of viruses and other microorganisms. The 
glycosaminglycan heparan sulfate has been identified as a potential HCV cellular 
receptor (Barth et al., 2003). Heparin, which is a homologue of highly sulfated 
heparan sulfate, was able to bind HCV E2 in an ELISA, in a concentration-dependent 
manner. The pretreatment of HCVpp and HCVcc with heparin and highly sulfated 
heparin inhibited the infectivity of Huh7 cells. 
A recent study identified occludin, a four transmembrane domain protein present in 
the tight junctions of polarized epithelial cells, as another HCV cellular receptor 
(Ploss et al., 2009). HCV permissive Huh7 or other cell lines like HepG2 cells were 
found to express detectable levels of occludin. Silencing of occludin expression lead 
to inhibition of HCVpp infection in Hep3B cells and, furthermore, to inhibition of 
infection of HCVpp and HCVcc in Huh7.5 cells. 
Additionally, there is evidence that the LDL receptor, a single pass transmembrane 
glycoprotein, is involved in the HCV infection process. The function of the LDL 
receptor is a sequestering of cholesterol in the form of LDL and VLDL (very low 
density lipids) from circulation. It was shown that binding of HCV particles obtained 
from positive serum of patients to human dermal fibroblasts were inhibited by 
pretreatment of cells with purified LDL and that the expression of LDLR on COS-7 
cells led to HCV binding to cells from 7 out of 12 patient sera (Monazahian et al., 
1999). Treatment of hepatocytes with monoclonal antibodies against LDLR or LDL 
also inhibited HCV infection (Molina et al., 2007). 
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 Thus, the available data indicate that there are at least three cell molecules important 
for HCV entry: CD81, SR-BI, and claudin-1. Contributions of other factors, such as 
glycosaminoglycans, LDL receptor, or occludin, have to be analyzed in more detail.  
Relatively little is known about domains in the E1/E2 heterodimers involved in 
reaction with the cell receptors. Several CD81-binding sites were identified in the E2 
molecule (Zeisel & Baumert, 2009)- Besides these binding regions, the HVRI, a  
27 a.a. segment at the N-terminus of E2 has been suggested to play a role in cell 
attachment (Penin et al., 2001). This region is known to evolve rapidly in infected 
individuals due to strong immune pressure driven by the host. HCV clones lacking 
the HVRI showed attenuated infectivity in chimpanzees, suggesting that the HVRI 
plays an important role in HCV infectivity (Forns et al., 2000). Additionally, deletion of 
HVRI significantly reduced HCVpp infectivity (Bartosch et al., 2003c). Most recent 
data suggest that HVRI is involved in interaction with the SR-BI receptor  
(Dreux & Cosset, 2007). 
1.5 The immune response during a HCV infection 
1.5.1 The innate immune response 
The innate immune response is induced in the early stages of HCV infection. A group 
of innate immune receptors, referred to as PRRs, recognize pathogen-associated 
molecular patterns (PAMPs) and coordinate the innate immune response. During the 
HCV infection, a viral double strain RNA (dsRNA) is bound by the receptors TLR-3 
and RIG-I inducing a signaling cascade, by which the synthesis of Type I interferon is 
induced. The release of IFN by infected hepatocytes or plasmacytoid dendritic cells 
induces the transcription of IFN-stimulated genes leading to an increased IFN 
production via a positive feedback mechanism. Type I IFN enhances furthermore the 
expression of human leukocyte antigen (HLA) class I on the surface of antigen-
presenting cells reinforcing the cellular immune response. Moreover, effector proteins 
such as PKR, which inhibits translation, or OAS, which induces viral mRNA 
degradation, are produced (Bode et al., 2007). It was shown, that the signaling 
cascades are detectable during the first two days of infection (Bigger et al., 2001). 
Despite the cellular IFN production and IFN therapy of infected patients, in some 
individuals HCV can persist. HCV developed several mechanisms that allowed 
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 evading the innate immune respnses. Thus, it was shown, that distinct viral proteins 
like NS3/4A and core are able to inhibit signaling pathways. Besides type I IFN, 
natural killer cells (NK), natural killer T cells (NKT) and myolide Kupffer cells play an 
important role in anti-HCV innate immune response (Crispe, 2003; Racanelli & 
Rehermann, 2006). The Kupffer cells are liver specific macrophages, which eliminate 
apoptotic cells or microorganisms via phagocytosis. In addition, they induce  
NK cell- and cytotoxic NK cell differentiation, which, in turn, lead to a production of 
high amounts of IFN (Lauwerys et al., 2000). NK cells are activated by type I IFN, 
lyse the infected cells and produce IFN-. This cytokine stimulates hepatocytes to 
produce the chemokine CXCL9 for the recruitment of T cells, acting as key factors for 
the adaptive immune response. NKT cells have the characteristics of NK cells and  
T cells and exist mainly in the liver where they activate dendritic cells to promote the 
secretion of high amounts of IFN-. 
1.5.2 The adaptive cellular immune response  
Despite a very early innate immune response during infection, the adaptive cellular 
immune response seems to be crucial for viral clearance. The acute phase of an 
HCV infection endures approximately 6 months post infection (p.i.), whereas the viral 
titer increases exponentially during the first 6 weeks. HCV-specific T cells are 
typically became detectable 5-9 weeks after infection (Thimme et al., 2001) and are 
crucial for viral clearance (Lechner et al., 2000). Virus-specific CD4+ and CD8+ 
T cells are accumulated in the liver by about 8-14 weeks after infection and this event 
coincides with viral clearance and liver disease. After depletion of CD4+ and CD8+ 
T cells the chimpanzees were unable to control viral replication (Cooper et al., 1999). 
Available data allow concluding that spontaneous clearance in the acute phase of 
infection can be associated with a strong sustained T cell response. Whether IFN- is 
directly involved in HCV clearance or whether it is just a marker for other T cell 
functions remains unclear.  
CD8+ T cells are detectable in the blood of acutely infected patients regardless of 
virological outcome (Kaplan et al., 2007). They show an impaired proliferation, IFN- 
production, cytotoxicity and increased levels of programmed death-L ((Kasprowicz et 
al., 2008; Thimme et al., 2001). CD8+ T cells start producing IFN- as well as TNF- 
(Tumor necrose factor ) after recognition of antigens presented by MHC class I 
molecules on the surface of infected cells in the liver or in the blood. Afterwards, they 
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 develop a cytotoxic activity, which involves FAS- mediated apoptosis via perforin and 
granzyme. IFN- production leads to a non-cytolytic control of infection involving, for 
example, the proliferation block, activation of macrophages, and upregulation of MHC 
molecules. A strong CD4+ T cells response seems to be also essential for viral 
clearance. These cells are required for the induction and maintenance of  
virus-specific CD8+ T cells.  
Chronic HCV infection is associated with continuous activation yet impaired function 
and reduced breadth of HCV-specific T cells (Cox et al., 2005). Several studies 
showed a weak or not detectable CD4+ and CD8+ T cell response during the HCV 
persistence. Detected cells have only limited functions, namely, decreased 
cytotoxicity, cytokine secretion or proliferation (Ulsenheimer et al., 2003). Reasons 
for the impairement of T cell response seem to be dysfunction or an increasing 
exhaustion during presence of high viremia. Mechanisms causing the T cell failure 
include an immune escape (Timm et al., 2004), presence of regulatory T cells 
(Sugimoto et al., 2003), or the increased expression of the co-receptor programmed 
death-1 on T cells.  
1.5.3 The humoral immune response 
Viral proteins are recognized as non-self by the immune system of the host and 
induce the production of antibodies (Abs). During the natural course of infection, Abs 
targeting epitopes of both structural and non-structural proteins are produced. Only a 
fraction of Abs that are able to bind the viral particles demonstrate antiviral activity. 
These Abs are directed against epitopes that play an essential role in the virus entry 
and reffered to as “neutralizing Abs” (nAbs) (Keck et al., 2008). Virus neutralization 
correlates with increased antibody binding to virion surface sites independent of the 
epitope recognized by the antibody. Virus neutralization results depend upon a 
critical number of occupied binding sites. This process result in prevention of virus 
entry through steric hindrance (Burton et al., 2001). Higher affinity Abs demonstrate a 
high virus neutralization, whereas non-neutralizing Abs either do not bind to virion 
surface or bind with a low affinity. Virus-specific antibodies are usually become 
detectable approximately 7-8 weeks after infection (Pawlotsky, 1999), whereas HCV 
RNA is detectable already one week p.i. coinsiding with an early appearance of  
HCV-specific T lymphocytes. Antibody-mediated neutralization occurs during HCV 
infection in vivo but the exact contribution of humoral immune response to the control 
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 of HCV infection is not completely clear. The occurrence of antibody-mediated 
neutralization in hepatitis C patients has been proposed after studying the patients 
undergoing liver transplantation for HCV-related liver cirrhosis - the infusion of  
anti-HBs hyperimmune globulin containing anti-HCV seemed to reduce HCV infection 
in the transplanted liver (Feray et al., 1998). Furthermore, it was shown that HCV-
infected patients with primary antibody deficiencies have accelerated rates of disease 
progression (Chapel et al., 2001). Another study demonstrated a passive protection 
against HCV in a cohort of patients who had been administered immunoglobulin 
preparations derived from HCV RNA-positive plasma (Yu et al., 2004).  
Theoretically, the neutralizing antibodies might be used for therapeutical purposes. At 
that, one approach to control re-infection of transplanted liver could be the combined 
use of HCV-specific antibodies together with specific antivirals. However, so far, the 
role of nAbs in preventing and controlling HCV infection has not been completely 
defined. Early experimental studies in animals have shown that Immunoglobulin  
G (IgG) therapy delayed the onset of acute infection in HCV-infected chimpanzees 
(Krawczynski et al., 1996). In addition, it was shown that a complete protection can 
be achieved if the HCV inoculums were pre-incubated with HCV–specific Ig (Farci et 
al., 1996). Studies in patients also demonstrated that serum antibodies from 
chronically HCV infected patients are directed against the HVRI (Rosa et al., 1996; 
Shimizu et al., 1994), supporting the supposition that the humoral immune response 
to this variable region contribute to some extend to protection against HCV infection.  
In the acute phase of HCV infection approximately 20 to 25 % of acutely infected 
individuals clear the viremia. A study of intravenious drug users, in which a 
comparison of previously HCV–infected individuals (HCV antibody-positive and HCV 
RNA-negative) with those without evidence of prior infection (HCV antibody-negative 
and HCV RNA-negative) was performed, demonstrated that individuals with evidence 
of a previous infection were 12 times less likely than those with first time exposure to 
develop persistence of HCV. Noteworthy, that the peak viral load was approximately 
10-1.8 lower in previously infected drug users (Mehta et al., 2002), suggesting that the 
adaptive humoral immunity can prevent a disease progression. Recently, the HCVpp 
and HCVcc model systems were established. That allowed the initiation of the 
functional studies directed at analysis of neutralizing antibody responses during 
acute and chronic HCV infections. Studies using well defined nosocomial or single-
source HCV outbreaks with a defined inoculum enabled investigation of a role of 
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 isolate-specific nAbs in a control of HCV infection in humans (Zeisel et al., 2007a). 
Thus, one recent study, in which serum samples of the well characterized single-
source outbreak were used, demonstrated that viral clearance was associated with a 
rapid induction of neutralizing antibodies in the early phase of infection (Pestka et al., 
2007). In contrast, in the same cohort of patients it was shown that chronic HCV 
infection was characterized by absence or low-titer of nAbs in the early phase of 
infection (Pestka et al., 2007). Patients, who cleared the virus, exhibited a broader 
cross-neutralizing activity of antibodies in the early phase of infection. An impaired 
ability to cross-neutralize viral variants that rapidly emerged during acute infection 
may thus contribute to viral evasion from neutralizing response in persistent HCV 
infection (Pestka et al., 2007). These findings suggest that a strong broad 
neutralizing antibody response may contribute to control HCV in the acute phase of 
infection.  
Patients, who do not clear the virus, usually develop relatively high-titer cross-
neutralizing antibodies during the chronic phase of infection (Bartosch et al., 2003a; 
Pestka et al., 2007; von Hahn et al., 2007). Paradoxically, these antibodies are not 
able to control the infection. Some data suggest a possible existence of an escape 
mechanism that allowed the virus to avoid antibody-mediated neutralization  
(von Hahn, Yoon et al. 2007). It is well known that in every infected individual the 
HCV exists as a pool of quasispecies, closely related but still slightly different 
variants. These subvariants are changed over time due to an immune pressure 
driven by the host and this, in turn, might lead to appearance of the virus variants that 
escape the antibody-mediated neutralization (Bartosch et al., 2003a). The escape 
mechanism hypothesis, however, needs confirmation. In particular, it would be 
essential to study if the mechanism of the humoral response escape is operative in 
all patients, including those with a long history of HCV persistence.  
1.6 Envelope proteins and the humoral immune response 
It is assumed that the virus-neutralizing antibodies might block the HCV binding to its 
cell receptors. Development of the HCVpp system open a new avenue of HCV 
research directed at analysis of interaction of HCV particles and of the E1 and E2 
proteins with antiviral antibodies. Available data suggest that the virus-neutralizing 
antibodies might react with both E1 and E2 proteins, however, most of the antibodies 
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 formed during the course of natural infection are targeting the E2 protein (Zeisel et 
al., 2007a). Even though most of these nAbs demonstrate a broad virus neutralizing 
capacity against conformational epitopes within E2, it was reported that there are Abs 
that are directed against linear epitopes. It was demonstrated that several antibodies 
targeting different linear regions within E2 can inhibit the E2-CD81 interaction in  
in vitro assays. The first Ab-binding site is located immediately downstream of the 
second hypervariable region between the positions 480 and 493 (Flint et al., 1999), 
whereas the second site spands residues 528 to 535, and the third site comprises 
the residues at positions 544 to 551 (Owsianka et al., 2001). Furthermore, it was 
shown, that Abs targeting the regions located at positions 412-423 and 432-447 are 
also able to block CD81 binding. However, the antibodies recognizing the regions 
480-493, 528-535 and 544-551 failed to neutralize HCVpp infection of target cells 
(Hsu et al., 2003). The region corresponding to a.a. positions 432-447 demonstrates 
a high variability among different HCV isolates, so that antibodies directed against 
this region have a restricted cross-neutralizing potency (Owsianka et al., 2005). The 
region spanning aa 412-423 has been shown to contain a potent neutralizing epitope 
(Triyatni et al., 2002), which is defined by the mouse monoclonal antibody (mAb) 
AP33 and a rat mAb 3/11. These two mAbs were able to inhibit the interaction 
between CD81 and a set of different molecules, including a soluble E2, E1/E2 
heterodimer and virus-like particles (Owsianka et al., 2001). Moreover, AP33 
efficiently neutralized the HCVpp bearing envelope sequences from all six HCV 
genotypes and major subtypes (Owsianka et al., 2005). The rat mAb 3/11 also 
neutralized diverse HCVpp, but with a lower potency than AP33. Fine mapping 
identified four highly conserved residues within the region 412-423 crucial for the 
binding of AP33. For the mAb 3/11 three critical residues were found, of which two 
are shared with mAb AP33 (Tarr et al., 2006). A broad sequence analysis of over 
5.500 sequences demonstrated that the AP33 epitope is highly conserved across all 
isolates of HCV. These data led to a suggestion of inclusion of such a conservative 
fragment of the E2 into the newly generated vaccines. In another study, six murine 
monoclonal antibodies CET-1 to -6, specific for HCV E2 protein were generated by 
using recombinant proteins containing truncated E2. The data indicated that three 
overlapping epitopes recognized by CET-1 to -6 are located in a small domain 
spanning a.a. residues 528 to 546 (Lee et al. 1999). Early studies have shown that a 
rabbit hyperimmune serum directed against HVRI of E2 is able to protect 
chimpanzees against HCV challenge (Farci et al., 1996). In addition, it was 
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 demonstrated that patient antibodies to HVR1 were capable to specifically block the 
E2 binding to cells (Scarselli et al., 2002), and to inhibit the entry of HCV virus-like 
particles and serum-derived HCV (Barth et al., 2005; Steinmann et al., 2004), as well 
as HCVpp into target cells (Bartosch et al., 2003a; Owsianka et al., 2005). Deletion of 
the HVRI showed an attenuation of virus infectivity in the chimpanzee model as well 
as in the HCVpp assay (Bartosch et al., 2003c). Recently, it was demonstrated that 
the deletion of the HVRI led to an enhanced neutralization of HCV particles by  
E2 specific mAbs (Bankwitz et al.) It should be noted, however, that due to a high 
variability in the region, antibodies directed against the HVRI show relatively low 
cross-neutralization potency across different isolates. Therefore, the generation of 
conserved HVRI mimotopes, which might overcome a problem of restricted 
specificity has been proposed (Wei et al., 2008; Zhang et al., 2003). 
Most of the antibodies that are able to interact with diverse strains of HCV are 
directed to conformational epitopes within E2. One intensive cross-competition study 
showed that the E2 glycoprotein contains three immunogenic conformational 
domains A, B and C. These domains are accessible on the surface of HCVpp  
(Keck et al., 2004). The spatial location of sites recognised by non-neutralizing and 
neutralizing human mAbs to conformational epitopes of E2 was established in a 
series of competition studies (Keck et al., 2005). The human mAbs CBH-4G, -4B and 
-4D are directed against domain A. The second domain B is characterized by 
reactivity with Abs CBH-2, -5, -8E and -11, and the third domain C is recognized by 
Abs CBH-7 and -23. Within a domain the human mAbs have significant bidirectional 
inhibition and minimal competition with each other in other domains. Human mAbs 
that target the domains B and C also inhibit E2-CD81 interaction. Human mAbs that 
recognize the domain A are not able to neutralize the HCVpp. Recently, these results 
were confirmed in experiments with HCVcc (Keck et al., 2007). Antibodies that 
recognize domains B and C, in contrast to Abs reacting with domain A, were able to 
neutralize the infectious HCV particles, however, the domain C antibodies showed 
neutralizing activity only at a much higher concentration. In general, all these 
experiments support an immunogenic model of HCV E2 containing three functional 
antigenic domains. It should be noted, however, that the role of these and other 
antigenic domains of the E1/E2 heterodimer in humoral immune responses in vivo is 
far from being completely clear and needs to be studied in much more details. 
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 1.7 The goals and aims of the study 
The major goals of the current project are:  
• Analysis of the evolution of the envelope protein genes of HCV in individual 
chronic hepatitis C patients infected in a single-source HCV outbreak  
(AD78 cohort). 
 
• Analysis of the dynamic of humoral immune response to these proteins and 
experimental verification of the hypothesis that chronic HCV infection is 
associated with a continuous escape of the circulating virus from emerging 
antibodies. 
 
To reach these goals we aim: 
• To characterise the E1 and E2 envelope genes sequences both in 
contaminated globulin and AD-infected patients chronically infected with the 
HCV AD78 strain using a phylogenetic analysis. 
 
• To perform a longitudinal analysis of AD78-derived sequences from 
chronically infected patients, including determination of dS/dN ratio, 
characterisation of a dynamic, localization and pattern of a.a. substitutions in 
envelope proteins. 
 
• To generate a series of HCVpp bearing the natural and modified E1/E2 
sequences from AD78 isolates obtained from AD-patients at different time 
points of chronic infection and to test their infectivity. 
 
• To use the generated set of HCVpp to analyse the characteristics of 
antibodies to envelope proteins present in serial serum samples of patients 
chronically infected with HCV AD78 strain, in particular, to assess the ability of 
these sera to neutralize the pseudoparticles bearing the evolving E1/E2 
sequences obtained from AD-patients during the follow-up of 28 years post 
infection. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Human sera from chronically infected HCV patients 
Sera of patients infected with the AD78 strain were kindly provided by  
Prof. M. Wiese, St.Georg Hospital, Leipzig, Germany. Between August 1978 and 
March 1979, 14 HCV1b contaminated batches of anti-D immunoglobulin had been 
administered to 2867 women throughout East Germany for prophylaxis of rhesus 
factor incompatibility. After application of the contaminated globulin, 93 % of the 
recipients developed an acute hepatitis C. After 25 years, 86 % of the 1833 affected 
women still tested positive for hepatitis C virus antibodies and 46 % for HCV RNA 
(Wiese et al., 2005). For the current study, nine anti-D patients, who developed a 
chronic hepatitis C and remain HCV RNA positive, were chosen. All these patients 
received anti-D globulin, batch #8. Five patients were not treated with IFN-. For 
other patients, except patient X, serum samples were obtained before start of the 
IFN-therapy. Serum sample of patient X was obtained 3 years after unsuccessful 
IFN- therapy (Table 2.1.). 
Table 2.1. Designation of patients and attitude of therapy 
Short form for the 
patient used in the 
current study 
Year of IFN-therapy 
T No 
N No 
Z 2005 
H No 
X 1995 
B No 
J 
M 
Y 
No 
2003 
1998 
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 2.1.2 Chemicals 
ß-mercaptoethanol      Sigma-Aldrich 
Acrylamide 2 K solution     AppliChem 
Agarose       Eurogentec 
Ampicillin (50 g/ml)     Roche Diagnostics 
APS        Roth 
Bromophenol Blue      SIGMA Aldrich Chemie GmbH  
Carbenicillin (50 g/ml)     Serva 
Coomassie Brillant Blue     Serva 
D-PBS       Invitrogen 
Dimethyl sulfoxide      Roth 
DMEM       PAA Laboratories 
EDTA Lösung pH8,0     Applichem 
ECL Western Blotting Reagents    GE Healthcare 
0.5 M EDTA pH8.0      Ambion (UK) 
Ethanol       Sigma-Aldrich 
Ethidiumbromide      Roth 
FBS        Gibco Invitrogen 
Geneticin (G 418)     PAA Laboratories  
Glycerol      SIGMA  
HEPES       PAA Laboratories 
Hydrogen Peroxide     Merck 
Isopropanol       Roth 
Lectin       Sigma 
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 L-Glutamin       PAA Laboratories  
Natrium Acetat      Merck 
Natrium Acetat 3M pH5,5     Ambion 
Natrium Chloride      Merck 
OPD        Sigma-Aldrich 
Orange G       Sigma-Aldrich 
Penicillin/Streptomycin     PAA Laboratories 
High Sensitivity Streptavidin-HRP   Pierce 
Sodium dodecyl sulfate (SDS)    AppliChem 
TBE ultrapure 10x      Invitrogen 
TEMED       Roth 
Triton X-100       Invitrogen  
Trizol        Invitrogen 
Trypan Blue       Gibco BRL 
Trypsin-EDTA      Gibco BRL 
Tween 20       Applichem 
X-Gal       Bio Solve LTD  
2.1.3 Equipment 
Device      Supplier 
Automatic incubator CO2     Kendro GmbH 
Balance      Vibra 
Bioimaging System (Gene genius)  Syngene  
Centrifuge 3 LR      Kendro GmbH 
 25 
2 Material and Methods 
 Centrifuge 5804      Eppendorf  
Centrifuge 5414 R      Eppendorf  
Duomax 1030     Heidolph 
Electrophoresechamber    Medicin-technique, Uniklinkum Essen 
Electrophorese-Power supply    Biometra 
Elisa Reader Asys Expert Plus    Asys Hiteck GmbH  
Freezer      Liebherr 
Fridge       Liebherr 
GeneAmp PCRSys 2400     Roche 
Gene Pulser II      BioRad Laboratories 
Hera Safe Flow      Kendro GmbH 
Heraeus CO2 Inkubator     Kendro GmbH 
Heraeus Megafuge 1.0 R     Kendro GmbH 
Heraeus Multifuge 3 LR     Kendro GmbH 
Inverted Microscope     Carl Zeiss  
Laminar Flow HSP 12     Kendro GmbH  
Luminometer      Siemens 
Microplate Scintillation and 
Luminescences counter    Packard  
Microwave      Panasonic 
Mini-Protean      Bio-Rad 
Mr. Frosty       Nalgene 
Pipette- Easypet      Eppendorf 
Pipettes       Eppendorf, Gilson 
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 Photometer Gene Quant     Amersham Biosciences Europe GmbH  
pH- Meter MP 220      Toledo 
Power-Pack      Bio-Rad 
Rotary Mixer      Peter Oehmen 
Thermocycler      Eppendorf 
Thoma counting chamber     Hecht-Assistant 
Topcount NXT      Packard 
Trans-Blot SD Transfer cell   Bio-Rad 
UV transluminator FLX-20M    MWG-Bio Tech 
Vacusafe comfort     IBS Integra Biosciences 
Vibra AJ-2200CE balance    Shinko Denshi 
Vortex Genie 2      Scientific Industries 
Waterbath       Julabo 
Zentrifuge 5415 D      Eppendorf 
Zentrifuge 5804      Eppendorf 
2.1.4 Commercial kits 
Bio-Rad Protein Assay Kit    Bio-Rad 
CalPhos Mammalian Transfection Kit  Clontech 
Expand High FidelityPLUS PCR System  Roche 
GloLysis Buffer     Promega 
High Speed Midi Kit     Qiagen 
InnotestTM HIV Antigen mAb    Innogenetics GmbH 
Qiagen Plasmid Maxi Kit     Qiagen 
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 Qiaprep Spin Miniprep Kit    Qiagen 
Qiaquick Gel Extraction Kit    Qiagen 
QIAquick PCR Purification Kit    Qiagen 
QuikChange Site-Directed Mutagenesis Kit  Stratagene 
TopoTA Cloning Kit     Invitrogen 
2.1.5 Plastic products 
FACS-Tubes Falcon/Becton    Dickenson 
Hybond N+ Membran     Amersham 
Dishes      Greiner Bio-One 
Nunc-Immuno Plate    Nunc 
Pipettes      Greiner Bio-One 
Reaction-tubes      Eppendorf 
Plastic tube with V-buttom    Falcon/Becton Dickenson 
Cell-culture flask      Greiner Bio-One 
Cell-culture plates     Greiner Bio-One 
2.1.6 Membranes 
Hybond-C nitrocellulose     Amersham  
2.1.7 Enzymes 
Go Taq-Polymerase (1 U/l)    Promega 
T4-DNA-Ligase (20 U/l)     New England Biolabs GmbH 
SalI       Fermentas GmbH 
PsiI       Fermentas GmbH 
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 EcoRV      Fermentas GmbH 
BsrGI        New England Biolabs GmbH  
PvuI New England      Biolabs GmbH  
Shrimp Alkaline Phophatase (1 u/µl)  Fermentas GmbH 
ThermoScript™ Reverse Transcriptase  Invitrogen 
2.1.8 Oligonucleotides 
Primer designation  Sequences   Targeted genome region 
Sv79s  5’-GAA TGT CGT GAA GGA AGC AG-3’      pHCMV- 
             IRES 
Sv655s 5’-TAT AGA TAT CAT GGG GTA CAT TCC GCT CGT C-3’     E1 
Sv656as 5’-ATA TGA TAT CTT ACT CAG CCT GAG CTA TCA G-3’     E2 
Sv657s 5’-CTA CTT TTC GCT GGC GTC GAC GGC AAC ACC CAC AC-3’   E1 
Sv687as 5’-TTC GCC GAC CTC ATG GGG TAC-3’        E1 
Sv688as 5’-GCC GCA TTG AGG ACC ACC AGG-3’        E2 
Sv690as 5’-GTT TTG AGA GAG TCA TTG CAG-3’        E1 
Sv691s 5’-GTG GGG AAC TGG GCT AAG G-3’        E2 
Sv692s 5’-GCC TCG CCT ACT ATT CCA TG-3’        E2 
Sv709as 5’-TGC CAG CGA GGA GAG AAG GTG-3’        E1 
Sv710as 5’-GCC AGC GAG GAG AGA AGG TGA AC-3’       E1 
Sv711s 5’-TAT GTA CGT GGG GGA TCT TTG-3’       E1 
Sv713as 5’-CGC ACG TCT TGG TAA ACC C-3’        E2 
Sv714as 5’-GAA GCA GTC CGT GGG GCA AG-3’        E2 
Sv715s 5‘-CTC CTT AAC AAC ACG CGG-3‘        E2 
Sv716s 5’-GGG AGA ATG AGA CGG ACG TG-3’      E2 
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 Sv774s 5’-CGT ATC GCT GGG GGG AGA ATG-3’      E2 
Sv826as 5‘-GAA GCA GTC CGT GGG GCA RR-3‘      E2 
Sv827as 5‘-CGC ACG TCT TGG TRA ACC C-3‘      E2 
Sv828as 5’-AGA ACA GMG CGG CAA KRA ACC-3’      E1 
Sv831s 5’-ACT TTT CGC TGG CGT CGA CGG CGC CAC ACA TGC CGT 
   GGG ACA GGT CGG AAG CAG GGG CCT GAA GAG AGG AGA  
CGC-3’         HVRI 
Sv832as 5’-GTT GGT GTT TAT AAG CTG GAT CTT CTG CAC GGA CCC 
   GAT ATC AAA TGC AGC GTC TCC TCT CTT CAG GCC CCT G-3’ HVRI 
Sv833s 5’-ACT TTT CGC TGG CGT CGA CGG CGG GAC ACA TGC CCT 
   GGG GGT TAT CGG AGT GAG AGG TGG CGG CGG AGC TGG  
AAG CGC         HVRI 
Sv834as  GTT GGT GTT TAT AAG CGT GAT CTT CGT TCC TGG TCC ACC  
GCC AAA TGC GGC GCT TCC AGC TCC GCC ACC TCT C-3’  HVRI 
Sv864s 5’-GCT CAG AAG ATC CAG CTT ATA AAC ACC AAC GGC AGC-3’ E2 
Sv865as 5’-GCT GCC GTT GGT GTT TAT AAG CTG GAT CTT CTG AGC-3’ E2 
Sv868s 5’-CT ACT TTT TGC TGG CGT CGA CGG CAT GTC CGG GAC-3’ E1 
Sv869as 5’-GTC CCG GAC ATG CCG TCG ACG CCA GCA AAA AGT AG-3’ E1 
Sv874s 5’-CAG CGC CGC GTG CAA CTG GAC TCG AGG AGA GCG TTG-3’ E1 
Sv875as 5’-CAA CGC TCT CCT CGA GTC CAG TTG CAC GCG GCG CTG-3’ E1 
Sv883s 5’-CTA CTT TTT GCT GGC GTC GAC GGC ATG TCC GGG AC-3’ E1 
Sv884as 5’-GT CCC GGA CAT GCC GTC GAC GCC AGC AAA AAG TAG-3’ E1 
Sv885s 5’-CC CAG AAG ATC CAA CTT ATA AAT ACC AAT GGC AGC-3’ E2 
Sv886as 5’-GCT GCC ATT GGT ATT TAT AAG TTG GAT CTT CTG GG-3’ E2 
Sv887s 5’-GGA GAC GCT GCA TTT GAC ATC GGG TCC GTG CAG AAG-3’ HVRI 
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 Sv888as 5’-CTT CTG CAC GGA CCC GAT GTC AAA TGC AGC GTC TCC-3’ HVRI 
Sv917s 5’-CGA TCC AGC CTC CGG TTG ACC GAT CCT GAG AAC-3’         phCMV- 
           IRES 
Sv918as 5’-GTT CTC AGG ATC GGT CAA CCG GAG GCT GGA TCG-3’         phCMV- 
           IRES 
Sv929s 5’-CTA CTT TTT GCT GGC GTC GAC GGC ATG TCC GGG AC-3’ E1 
Sv930as 5’-GT CCC GGA CAT GCC GTC GAC GCC AGC AAA AAG TAG-3’ E1 
Sv931s 5’-CCC AGA AGA TCC AAC TTA TAA ATA CCA ATG GCA GC-3’ E2 
Sv932as 5’-CG TGC CAT TGG TAT TTA TAA GTT GGA TCT TCT GGG-3’ E2 
Sv933as 5’-GCC GTC GAC GCC AGC AAA AAG TAG C-3’    E1 
Sv934s 5’-GGC GTC GAC GCC AGC AAA AAG TAG C-3’    E1 
Sv936as 5’-GTA TTT ATA AGT TGG ATC TTC TGG-3’    E2 
Sv937s 5’-CAA CTT ATA AAT ACC AAT GGC AGC-3’    E2 
Sv939as 5’-GC AGG ACT AGT ATA TGA TAT CTT ACT CAG CCT GAG 
 CCT GAG CTA TCA G-3’       E2 
Sv940s 5‘-ATC CG TGT ACA TAT AGA TAT CAT GGG GTA CAT TCC 
 GCT CGT C-3’        E1 
Sv941s 5’-CTG TTC TAC ACA CAT AGC TTC AAC TCG TCC GG-3’  E2 
Sv942as 5’-CC GGA CGA GTT GAA GCT ATG TGT GTA GAA CAG-3’  E2 
Sv945s 5’-CTA GTC CTG CAG GTT TA-3’     pCR4Topo 
Sv945as 5’-GCC GCG AAT TCG CCC T-3’     pCR4 Topo 
Sv962s 5’-CGA TCC AGC CTC CGG TCT ACC GAT CCT GAG AAC TTC      phCMV- 
              IRES 
Sv963as 5’-GAA GTT CTC AGG ATC GGT AGA CCG GAG GCT GGA TCG     phCMV- 
             IRES 
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 Sv969s 5’-TA GAG AAC AAT TGT TAC AAT TAA ATG ATA AGG TAG-3’       phCMV- 
             IRES 
Sv970as 5’-CTA CCT TAT CAT TTA ATT GTA ACA ATT GTT CTC TA        phCMV- 
             IRES 
Sv971s 5’-CGG CAA AAT CCC TTA CAA ATC AAA AGA ATA GAC C-3’        phCMV- 
            IRES 
Sv972as 5’-G GTC TAT TCT TTT GAT TTG TAA GGG ATT TTG CCG-3’        phCMV- 
             IRES 
Sv978s 5’-TTA GTG AAC CGT CAG ATC GCC-3’           phCMV- 
             IRES 
Sv979as 5’-AAG TGC CAC CTA AAT TGT AAG-3’           phCMV- 
            IRES 
2.1.9 Plasmids 
Commercial plasmids 
The pCR4 Topo plasmid (Invitrogen, Germany) was routinely used for cloning of 
PCR products. 
Plasmid containing the envelope genes of HCV AD78 infected patients 
The phCMV-IRES plasmid (5520bp) was used for expression of the E1 and E2 
proteins of HCV. This plasmid contains the IRES of EMCV that drives the translation 
of the HCV Env genes. The inserted envelope protein genes were obtained during 
the amplification of HCV sequences from serum samples of AD patients collected at 
different time points. The generated set of plasmids was used for transfection of 
293T cells in order to produce the HCV E1/E2 heterodimer for ELISA for the 
generation of HCVpp. 
Plasmid containing HIV-Gag, Pol genes 
The lentiviral vector pCMV delta R8.2 (8128) has been obtained from Addgene 
(USA). This plasmid expresses the HIV Gag and Pol proteins in 293T cells and was 
used for production of HCVpp. 
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 Plasmid containing the luciferase reporter gene 
The HPPT-EF1- Luc HIV-1-based transfer vector contains the EF1  internal 
promoter, which drives the expression of Luc (luciferase reporter gene) gene. The 
plasmid was used for generation of HCVpp in 293T cells. 
2.1.10 Buffers and Solutions 
Carbonate Buffer (ELISA)  3.18 g Na2CO3 
     5.88 g NaHCO3 
     0.2 g NaN3 
     
5 % FCS (inactivated) (v/v) 
     5 µg/ml Lectin 
     Add H20 dest.to 1 liter 
     pH 9.6 
 
Blocking Buffer (ELISA)  3.18 g Na2CO3 
     5.88 g NaHCO3 
     0.2 g NaN3 
     
5 % FCS (inactivated) (v/v) 
0.1 % Tween 20 (v/v) 
 
Coating Buffer (ELISA)   30 mM Na2CO3 
70 mM NaHCO3 
2.5 µg/ml Lectin 
pH 9.6 
 
Coomassie Brillant-Blue-  0.06 % Coomassie brillant-blue R250 (w/v)  
 
Staining solution   50 % Methanol (v/v)  
10 % Acetic acid (v/v)   
     2 % negative Celllysat 
     2 % Mock 
     
Add H20 dest.to 1 liter 
     pH 9.6 
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 Destaining Solution   5 % Methanol (v/v) 
7.5 % Acetic acid (v/v) 
 
Dilution Buffer (ELISA)  0.1 % Tween 20 (v/v) 
     3 % FCS (v/v) 
     1-2 % neg. Celllysat 
     2 % Mock 
     2.5 µg/ml lectin 
     5 % Goat serum 
     Add PBS to 1 liter 
 
DNA-Loading Buffer   5.5 mM Orange G 
1.2 M Saccharose 
 
Lysis buffer (SDS-PAGE)  0.5 M Tris, pH 6.8 
     1 % Glycerol 
     10 % SDS 
     5 % 2-Mercaptoethanole 
     0.05 % Bromphenole-blue 
      
Cell Lysis Buffer   20 mM Tris HCL, pH 8.0 
     137 mM NaCl 
     10 % Glycerol 
     1 % Triton-X 100 
     2 mM EDTA 
     Add H20 dest.to 100 % 
 
OPD-Substrate Solution (1 tabl)  10 ml PBS 
10 l H2O2 
 
PBS      155 mM NaCl 
3 mM Na2HPO4 
1 mM KH2PO4 
pH 7.4 
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 Stop Solution    0.5 M H2SO4 
 
TBE-Buffer      100 mM Tris 
90 mM Boracic acid 
1 mM EDTA 
pH 8.4 
 
Washing Buffer (ELISA)   PBS 
0.5 % (v/v) Tween20 
 
4x SDS Loading Buffer  10 % Glycerine  
4 % SDS  
125 mM Tris, pH 6.8 
10 % 2-Mercaptoethanol  
0.02 % Bromphenol blue  
 
5x-DNA-loading-buffer  Glycerine 50 % 
20 mM Tris, pH 7.5 
50 mM EDTA, pH 8.0 
0.025 % Bromphenoleblue  
0.025 % Xylenecyanole  
 
10x Reaction-buffer   100 mM KCl 
100 mM (NH4)2SO4 
200 mM Tris-HCl (pH 8.8) 
20 mM MgSO4 
1 % Triton X-100 
1 mg/ml nuclease-free bovine serum albumin (BSA) 
 
10x TBE-buffer   Tris Base 108g 
      Boric acid 55g 
0.5 M EDTA, pH 8.0 
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 2.1.11 Antibodies 
Primary Antibodies 
• Mouse mAb CET-3 and CET-4 were kindly provided by Prof. Chang-Yuli Kong 
(South Korea) 
 
• Human mAb CBH-2, CBH-5, CBH-7, CBH-23, HC-1, and HC-12 Anti HCMV 
RO4 isotype control were kindly provided by Dr.Steven Foung (USA) 
Secondary Antibodies 
• Peroxidase-conjugated Affini Pure Rabbit anti-mouse 
IgG + IgM (H+L) – Dianova 
 
• Polyclonal Rabbit Anti-Human IgG/HRP - Dako Cytomation  
2.1.12 Medium for culture of E.coli 
LB Agar    10 g Trypton 
5 g Yeast extract 
5 g NaCl 
15 g Agar 
  
LB Medium    10 g Trypton 
5 g Yeast extract 
5 g NaCl 
 
Both media were completed to 1000 ml with bidistilled water and sterilized by 
autoclaving for 10 minutes at 121 °C. Ampicillin was added to each medium at a final 
concentration of 100 g/ml. 
2.1.13 Bacteria strains 
E.coli Strains    Supplier   
XL-10 Gold Ultracompetent cells  Stratagene GmbH  
Top 10 Competent cells    Invitrogen GmbH  
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 Strain Genotype Properties 
TOP10  
(Invitrogen) 
F- mcrA (mrr -hsdRMSmcrBC) 
80lacZM15lacX74 nupG recA1 
araD139 (ara-leu)7697 
galE15 galK16 rpsL(StrR) endA1 - 
• Streptomycin resistant 
• Contain lacI based on 
a colony PCR 
XL10-Gold 
(Stratagene) 
endA1 glnV44 recA1 thi-1 
gyrA96 relA1 lac Hte(mcrA)183 
(mcrCBhsdSMR-mrr)173 tetR 
F'[proAB lacIqZM15 Tn10(TetR 
Amy CmR)] 
• Tetracycline and 
Chloramphenicol 
resistant 
• Nalidixic acid resistant 
• Hte phenotype allows 
high transformation 
with large plasmid 
inserts 
2.1.14 Eucaryotic cell lines 
Human hepatoma cell line Huh7.5 
Huh7.5 cells are a subline derived from Huh7 hepatoma cells (Blight et al., 2002). 
This subline was established by “curing” a cell clone containing a Con1 subgenomic 
replicon by prolonged treatment with alpha-interferon. The receptors, important for 
the initiation of virus entry, are expressed on the viral surface and, therefore, these 
cells can be used for studying virus entry.  
Human Embryonic Kidney 293T cells 
293T cells are an important variant of the HEK 293 cells. This cell line bears the 
SV40 large T-antigen that allows episomal replication of transfected plasmids 
containing the SV40 origin of replication. In the current study 293T cells were used 
for generation of HCVpp. 
2.1.15 Used Software 
Codon Code Aligner   Codon Code 
Fig Tree     http://www.tree.bio.ed.ac.uk  
GraphPad Prism 4.03   GraphPad Software 
HCV Sequence Data Base  http://www.hcv.lanl.gov 
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 Microsoft Office     Microsoft 
NCBI Homepage     http://www.ncbi.nlm.nih.gov 
Nebcutter     http://www.tools.neb.com/NEBcutter2 
2.2 Methods 
2.2.1 Procaryotic Cells 
2.2.1.1 Transformation of E.coli 
Transformation of bacterial cells was performed according to the manufacturer’s 
instructions. In brief, bacterial cells (Top10 cells or XL10-Gold cells) frozen at -80 °C 
were thawed on ice. Two microliters of 2-Mercaptoethanol were added to 45 µl of 
XL10-Gold cells aliquot and incubated for 10 min. on ice. Top10 cells were used 
without addition of mercaptoethanol. No more than 10 % by volume of the plasmid 
DNA was added to the aliquote of bacterial cells. This mixture was incubated on ice 
for 30 minutes. To improve DNA absorption by bacteria, a heat shock for 30 sec. at 
42 °C followed by a subsequent incubation on ice for 2 minutes was performed. After 
addition of 250 l LB-medium a mixture was incubated on a shaker for 2 hours at  
37 °C. Using a sterile spatula the complete mixture was spread over an LB-agar plate 
containing a selective antibiotic. The plates were incubated overnight at 37 °C. 
2.2.1.2 Plasmid DNA preparation using commercial kits  
One bacterial colony was picked up from the LB agar plate, using a sterile pipette tip 
and transferred into the flask with LB-medium containing the ampicillin (5 ml of 
medium for minipreps, 100 ml- for midipreps, and 250 ml – for maxipreps). The 
bacteria culture was then incubated overnight on a shaker at 37 °C. The culture was 
then centrifuged at 5000 rpm for 10 min and cells were washed once with PBS. The 
DNA was extracted using the Qiaprep kits (Qiagen), according to the manufacturer’s 
protocol. DNA was quantified by spectrophotometry at 260 nm and the size of the 
plasmid was checked using the electrophoresis in agarose gel. 
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 2.2.2 Molecular Biological Methods 
2.2.2.1 RNA-Extraction from human sera  
HCV RNA was extracted from patients’ sera using the High Pure Viral RNA Kit 
(Roche) according to the manufacturer’s instructions. In brief, 200 l serum was 
mixed with the Binding Buffer supplemented with Poly (A), transferred into a filter 
minicolumn, and centrifuged for 30 sec. at 8000 x g. Afterwards, 500 µl Inhibitor 
Removal Buffer was added to the upper reservoir followed by centrifugation for  
1 min. at 8000 x g. The column was washed 2 times with 450 µl Wash Buffer. Viral 
RNA was eluted in 50 µl of Elution Buffer and directly used in the reverse 
transcription reaction or kept at -80 °C. 
2.2.2.2 Reverse-Transcription 
HCV RNA isolated from patient’s sera was reverse transcribed into cDNA using the 
Thermoscript kit (Invitrogen) according to the following procedure: 
RT reaction Mix I 
Primer (50 pmol/l)    1 l 
dNTPs (5 mM)     2 l 
RNA      5 µl 
RNAse free Water    5 µl 
        13 µl 
The RNA in Mix I was denatured for 5 min at 65 °C and directly cooled down on ice. 
RT reaction Mix II 
5x cDNA Synthesis Buffer   4 l 
0.1M DTT      1 l 
Rnase Out (20U)     1 l 
RNAse free Water    1 µl 
       7 µl 
Mix II was added to Mix I to a final volume of 20 µl and incubated for 1 h at 50 °C, 
followed by additional incubation step (5 min. at 85 °C). Five µl of generated cDNA 
was used for PCR 1. 
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 2.2.2.3 Polymerase Chain Reaction (PCR) 
All the cDNA were amplified in a nested touchdown PCR using the Expand High 
Fidelity PCR System. Two separate master mixes were prepared and mixed at a  
50 l final reaction: 
Mastermix PCR1 
5 x Reaction-Buffer with MgCl2      10 µl 
dNTPs (10 mM)           1 l 
Primer Sens (10 pmol/l)            5 l 
Primer Anti-sens (10 pmol/µl)         5 l 
cDNA              5 µl 
High Fidelity Polymerase (5 U/ml)     0.5 µl 
H2O      23.5 µl 
         50 µl 
Mastermix PCR2 
5 x Reaction-Buffer with MgCl2      10 µl 
dNTPs (10 mM)            1 l 
Primer Sens (10 pmol/l)            5 l 
Primer Anti-sens (10 pmol/µl)         5 l 
DNA              2 µl 
High Fidelity Polymerase (5 U/ml)            0.5 µl 
H2O       26.5 µl 
         50 µl 
Touchdown PCR programme for both reactions: 
1. 95 °C   2 min. 
2. 95 °C   1 min.   
3. 66-57 °C  1 min. 2x until 57 °C 
4. 72 °C   3 min. 
5. 95 °C   1 min. 
6. 57 °C   1 min. 15x 
7. 72 °C   3 min. 
8. 72 °C  20 min 
9.  4 °C  forever 
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 The size of amplified DNA fragments was assessed using the ethidium bromide 
agarose gel electrophoresis. 
2.2.2.4 Side-directed mutagenesis (SDM) 
Quick-Change site-directed mutagenesis kit (Stratagene) was used to introduce 
single point mutations into the plasmid sequences. In this technique two 
complementary mutagenic primers, containing the desired nucleotide are used to 
amplify the entire plasmid. The non-strand-displacing action of the Pfu Ultra HF DNA 
Polymerase extends and incorporates the mutagenic primers, which results in a 
formation of nicked circular strands. After touchdown PCR, the methylated parental 
plasmid DNA is removed by digestion with DpnI.  
Standard SDM Mixture: 
reaction buffer (10x)      5.0 l  
plasmid (100 ng in 5 µl)      5.0 l  
Sens primer 5’- 3’ (10 pmol/l)     1.5 l  
Anti-sense primer 3’- 5’ (10 pmol/l)   1.5 l  
Stratagene dNTP-mix     1.0 l  
Quick solution     3.0 µl 
PfuUltra HF DNA Polymerase (2.5 U/l)  1.0 l  
H2O                   32.0 l 
         50 µl 
Touchdown PCR programme for SDM: 
1. 95 °C  3 min. 
2. 95 °C  1 min. 
3. 66°-60 °C 1 min.   3x 
4. 68 °C  3 min. 
5. 95 °C  1 min. 
6. 60 °C  1 min.  15x 
7. 68 °C  7 min. 
8.  4 °C 
After PCR, 1 µl DpnI was added to the PCR-product and the mixture was incubated 
1h at 37 °C. Afterwards, 1 µl of the mixture was used for transformation of XL-10 
Gold cells (2.2.1.1.). 
 41 
2 Material and Methods 
 2.2.2.5 DNA restriction 
Plasmids and PCR-products were restricted either with a single endonuclease or with 
combination of two enzymes. When the enzymes used for plasmid restrictions had 
different optimal temperatures or when they did not work in a compatible buffer, 
sequential restrictions were carried out using the optimal buffers and temperatures. 
Restriction of plasmids with one endonuclease: 
DNA (3-5 g)       x l 
10 x Buffer         10 l 
10 x BSA         10 l 
Enzyme (50 U)        y l 
H2O       z µl 
   100 l 
The restriction was carried out overnight at the optimal temperature depending on the 
endonuclease used. 
Restriction of plasmids with two endonucleases: 
DNA (3-5 µg)   x l 
10 x Buffer        10 l 
10 x BSA       10 l 
Enzyme 1(50U)        y l 
Enzyme 2(50U)        z l 
H2O             l 
        100 l 
The restriction was carried out overnight at the optimal temperature for both 
endonucleases. Afterwards, the restricted DNA was subjected to a control 
electrophoresis in agarose gel. The desired DNA fragments were cuted out and 
subjected to a purification using the QIAprep Gel Extraction Kit (Qiagen). 
2.2.2.6 DNA Dephosphorylation  
In some cases, e.g. when only one enzyme was used for restriction of the plasmid, in 
order to prevent a re-ligation of a linearized plasmid, the restricted DNA was 
incubated with 3 µl Shrimp alkaline phosphatase (1 U/µl) for 1 h at 37 °C.  
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 Afterwards, the enzyme was inactivated by an incubation for 20 min. at 80 °C. 
Finally, a purification step using the Qiaquick Gel Extraction Kit (Qiagen) was 
performed. 
2.2.2.7 Agarose gel electrophoresis 
DNA fragments were separated in a horizontal submerged 1-2 % agarose gel 
containing the ethidium bromide. The visualization of the separated DNA fragments 
was performed using a UV- Bioimaging System (Syngene). 
2.2.2.8 DNA Extraction from agarose gels 
Restricted plasmids or amplified DNA fragments were separated by agarose gel 
electrophoresis. The fragments of interest were cuted out of the gel and purified with 
the QIAprep Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. 
2.2.2.9 Cloning of PCR-products in intermediate plasmids 
In most cases the amplified DNA fragments were cloned in pCR4-Topo plasmid 
(Invitrogen) without additional gel purification, according to the manufacturer’s 
protocol.  
pTopo cloning mixture: 
PCR product (treated with Taq)   2 l 
Salt solution      1 l 
pCR4-Topo - vector    1 l 
H2O       2 l 
      6 µl 
The mixture was incubated for 45 minutes at RT and 2 ul were used for 
transformation of 25 l supplied TOP 10 cells according to the standard protocol 
(2.2.1.1.).  
2.2.2.10 Ligation of DNA Fragments 
Purified restricted vector DNA and insert DNA were used for the ligation using the  
T4 DNA ligase. A 1:5 or 1:6 molar ratio of vector to the insert DNA was normally 
used. 
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 Ligation mixture: 
Vector DNA     100 ng 
Insert DNA           x ng 
10x ligation buffer            2 l 
T4 DNA ligase (Weiss units)         1 u 
Nuclease-Free water         y l 
           20 µl 
The ligation mixture was incubated ON at 16 °C and 3 µl were used for the 
transformation of competent cells (2.2.1.1.). After transformation, single colonies 
were picked for Mini DNA preparation (2.2.1.2.) and the purified plasmid DNA was 
subjected to a control restriction (2.2.2.5.), followed by sequencing (2.2.2.11). 
2.2.2.11 DNA-Sequencing 
Sequencing was performed in both directions and was outsourced to the company 
AGOWA, Berlin.  
Throughout the thesis the following sequence designation system was used: 
For the E1 gene, the first nt is located at the position 384, the last nt as a  
position 576. The a.a. sequence of the E1 protein starts at position 1 and ends at 
position 192.  
For the E2 gene, the first nt is located at the position 577, the last nt at a  
position 1086. The a.a. sequence of the E2 protein starts at position 1 and includes 
the four additional a.a. and ends at position 362. 
In the result section 3.3 the positions of the additional nt or aa located between E1 
and E2 sequences are indicated as positions -1. -2, -3, etc. 
2.2.3 Cell culture 
2.2.3.1 Culture of Huh7.5 cells 
Adherent Huh7.5 cells were grown in monolayers in Dulbecco’s modified minimal 
essential high glucose medium (4,5 g/l) with L-glutamine supplemented with 15 % 
FBS, 0.5 % gentamycin and 1 % non-essential amino acids. Cells were passaged 
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 two times a week at a dilution of 1:3 or 1:5 depending on the confluence. Briefly, the 
medium was removed from the cells. Then, the cells were washed with 5 ml PBS and 
2 ml of Trypsin-EDTA were added until the cells were covered. After 2 minutes the 
trypsin-EDTA was removed and after additionally 2-4 minutes, the cells started to 
detach from the bottom. Immediately, 10 ml of fresh medium was added to the cells. 
Finally, after resuspension, the cells were transferred to a new flask at a 
corresponding dilution.  
2.2.3.2 Culture of 293T cells 
Adherent 293T cells were grown in monolayers in Dulbecco’s Modified Eagle 
Medium 1x (Gibco) containing 4.5 g/l glucose, L-glutamine, and 25 mM Hepes. It was 
supplemented with 10 % FCS and 1 % Penicillin/Streptamycin. Cells were passaged 
2 times a week at a dilution of 1:10 or 1:15 depending on the confluence. Briefly, the 
used medium was removed from the cells and 10 ml new medium was added. After 
gentle shaking the cell were detached, resuspended, and distributed to new flasks at 
proper dilutions. 
2.2.3.3 Cryoconservation of cells 
The cell suspension was centrifuged in Falcon tubes for 5 min. at 1200 rpm. The cell 
pellet was resuspended in 900 µl FCS and after that added into a cryotube containing 
100 µl DMSO. The cells were frozen slowly overnight at -80 °C using the Mr. Frosty 
device and were transferred to a liquid nitrogen tank the following day. 
2.2.3.4 Thawing of cells 
Cryo tubes containing cells were taken out from the liquid nitrogen and thawed under 
water. Next, the content was added to a flask containing 7 ml medium. After 4 hours 
culturing at 37 °C, the medium was changed to clear the cells from DMSO. 
2.2.3.5 Transfection of 293T cells 
293T cells were harvested and seeded in a 10 cm2 dish at a final concentration of  
2.5 x 106 cells in 8 ml medium (20-30 % confluence). The next day, the cells were 
transfected either with the expression plasmid phCMV IRES-E1/E2 (4 µg) for the 
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 production of E1/E2 heterodimers. Alternatively, for the generation of HCVpp, the 
293T cells were transfected with the expression plasmid phCMV IRES-E1/E2 in 
combination with 2 retroviral plasmids encoding for HIV-Gag,Pol or Luc (pCMV delta 
R8.2; plasmid HPPT-EF1- Luc) using the Calcium Phosphate Transfection Kit 
(Clontech). Briefly, 500 µl HBS 2x were put in a facs tube. Next, using an Eppendorf 
tube 1.5 ml, the mix was prepared as follows: 
Mix for the generation of E1/E2 heterodimers: 
1. H2O              x µl 
2. phCMV- E1/E2           4 µg 
3. CaCl2 solution (added dropwise)        62 µl 
 Final volume            500 µl 
Afterwards, this mix was added dropwise to the tube containing 500 µl of HBS 2x and 
incubated for 20 to 30 min at Rt until the mixture becomes cloudy. After addition of 
this cloudy solution dropwise to the cell culture, the dishes were incubated up to 16 h 
at 37 °C. The medium was changed and the cell culture was additionally incubated 
for 24 h at 37 °C. Finally, the cells were scrapped from the dishes and lysed. 
 Mix for the generation of HCVpp: 
1. H2O              x µl 
2. phCMV- E1/E2        2.7 µg 
3. plasmid encoding for Gag, Pol        8.1 µg 
4. plasmid encoding for Luc       8.1 µg 
5. CaCl2 solution (added dropwise)        62 µl 
Final volume         500 µl  
This mix was added dropwise to the tube with 500 µl of g HBS 2x and incubated for 
20 to 30 min. at Rt until the mixture becomes cloudy. After addition of this cloudy 
solution dropwise to the cell culture, the dishes were incubated up to 16 h at 37 °C. 
The medium was changed and the cell culture was additionally incubated for 48 h at 
37 °C. Finally the supernatant containing the generated HCVpp was harvested and 
centrifuged for 5 min at 1200 rpm. The HCVpp preparation was aliquoted, frozen at  
-80 °C, and used for infectivity assay or neutralization assay. 
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 2.2.3.6 Infectivity assay 
Huh 7.5 cells were seeded in 96 well plates. For each plate, a master mix with  
1.4 x 106 cells in 20 ml medium was prepared. The next day, the medium was 
removed and HCVpp in 100 µl of medium were added. After incubation for 4h at  
37 °C, 200 µl of fresh pre-warmed medium was added and plates were incubated for 
additional 72 h at 37 °C. For the infectivity evaluation, the medium was removed and 
50 µl of lysis buffer (Promega) was added to each well and incubated for 5 - 10 min 
at Rt using the shaker. Afterwards, 25 µl of prepared cell lysat were transferred into a 
luminometer 96 well plate. Twenty five µl of the Bright Glo Luciferase Assay buffer 
(Promega) were added and the luciferase-activity was immediately measured in the 
luminescence counter (Berthold Instruments). All cell lysates were measured in 
triplicates and a mean value was calculated. 
2.2.3.7 Neutralization assay 
Huh7.5 cells were seeded one day before neutralization as in 2.3.3.6. Dilutions of 
patients sera or monoclonal antibodies were prepared in DMEM and stored at 4 °C 
until the next day. The following day, HCV pp were thawed, mixed with the diluted 
sera or Abs, and incubated for 1 h at 37 °C. Afterwards, the mixture of HCVpp with 
sera or Abs in the volume of 50 µl was added to Huh-7.5 cells. The plates were 
incubated for 4 h at 37 °C. Afterwards, 200 µl medium were added to each well. The 
plates were finally incubated for 72 h at 37 °C. For the infectivity evaluation, the 
medium was removed and 50 µl lysis buffer (Promega) was added to the cells and 
incubated for 5 - 10 min. under shaking at Rt. Afterwards, 25 µl of prepared cell lysat 
was transferred into a luminometer 96 well plate. Twenty five µl of the Bright Glo 
Luciferase Assay buffer (Promega) was added to each well and the luciferase-activity 
was immediately measured in the luminescence counter (Berthold Instruments). The 
luciferase activity of all cell lysates was measured in triplicates and a mean value 
was calculated. Inhibition of infectivity by more than 50 % was considered as a 
positive neutralization.  
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 2.2.4 Biochemical and immunological methods 
2.2.4.1 Preparation of cell lysates 
The medium of the Petri dishes (10 cm2) containing the transfected 293T cells was 
removed and dishes were immediately put on ice. In the next step, the cell dish was 
transferred onto ice and 5 ml of ice cold PBS was added to each dish. The cells were 
scrapped and transferred into a 15 ml Falcon tubes. A centrifugation step for 5 min. 
at 1200 rpm at 4 °C was applied. The cell pellets were resuspended in 0.5 ml of  
non-denaturing lyses buffer and incubated on ice for 30 min. The mixtures were 
clarified by centrifugation for 20 min at 4 °C at 12.000 rpm. Finally, the supernatant 
was transferred into another Eppendorf tube and either stored at -20 °C or directly 
used for SDS-PAGE or ELISA. 
2.2.4.2 SDS-PAGE 
Proteins were separated using the standard discontinuous SDS-PAGE 
(sodiumdodecylsulfate-polyacrylamide-gel electrophoresis) in the Mini-Proteam 
(BioRad).  
  Stacking Gel    Separation Gel 12 % 
30 % Acrylamid solution (29:1)  0.75 ml    4.15 ml 
Tris-HCl (1 M, pH 6.8)   0.62 ml 
Tris-HCl (1.5 M, pH 8.8)         2.5 ml 
SDS 10 %     0.05 ml     0.1 ml 
H2O 3.55 ml                                        3.25 ml 
For polymerisation of the gels saturated APS solution (1:500) and TEMED (1:1000) 
were added. 
2.2.4.3 Immunoblot analysis (Western Blot) 
After the SDS-PAGE, the proteins were transferred from the gel to the nitrocellulose 
membrane. In this process membrane and gel were soaked in western-blot-transfer-
buffer and placed between three layers of Whatman paper without air bubbles. The 
gel was turned towards the cathode and the membrane was turned towards the 
anode. Transfer took place for 15 minutes at 7.5 V using the SemiDry-transfer 
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 chamber (Trans-Blot SD, BioRad). After the transfer, binding sites on the membrane 
were blocked with blocking buffer ON at 4 °C upon a gentle shaking. Anti-HCV- E1 or 
E2 antibodies were diluted due to their optimal binding capacity in blocking buffer 
before incubation with the membrane for 1 h or, alternatively, overnight at 4 °C. 
Following 3 cycles of washing with T-PBS for 10 minutes, the membrane was 
incubated for 1 h with conjugate (anti-mouse or anti-goat peroxydase labelled IgG) 
diluted 1:1000 in the blocking buffer. Additional 3 steps of washing with PBS 
followed. Binding of the conjugate to anti-HCV antibodies on the membrane was 
detected on a radiographic film (BioMax Film, Kodak) by using ECL Western blotting 
detection reagents according to the manufacturer’s instruction.  
2.2.4.4 Enzyme-linked Immunosorbent Assay (ELISA) 
The technique of the enzyme-linked immunosorbent assay (ELISA) is used to detect 
the presence of the AD patient E1/E2 antigen in prepared cell lysates (2.2.4.1.) and 
to characterize the binding capacity of antibodies included in patients’ sera to AD 
patients’ E1/E2 antigen.  
The Nunc immunoplates were coated with lectin (5 µg/ml) in a 0.1 M carbonate buffer 
(pH 9.6) ON at 4 °C. After blocking of the potential unspecific binding sites in the 
wells with the blocking buffer (incubation ON at 4 °C), the plates were washed  
4 times with PBST. Lysates of 293T cells transfected wuth the HCV E1/E2 
expressing plasmids were added to each well and plates were incubated ON at Rt. 
The wells were washed 4 times with PBST and primary antibodies (e.g. monoclonal 
antibodies to HCV E1 or E2 proteins) were added in a concentration of 1 µg/ml and 
incubated 3-4 h at 37 °C. Alternatively, human sera, diluted 1:50 in dilution buffer, 
were added to the wells and incubated 3-4 h at 37 °C. The wells were washed  
4 times with PBST. Secondary antibody labeled with HRP (anti-mouse 1:1000,  
anti-human 1:5000) was added and plates were incubated for 1 h at 37 °C. After 
additional washing with PBS 100 µl of OPD substrate solution was added to each 
well, the plates were incubated in the dark for 1-10 minutes, and the reaction was 
stopped by adding 50 µl of the Stop solution. Finally, the OD490nm was measured 
using the Elisa Reader Asys Expert Plus (Asys Hiteck).  
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 2.2.4.5 P24 assay 
For quantification of HCVpp produced in 293T cells, the commercial InnotestTM HIV 
Antigen mAb kit (Innogenetics GmbH) for the evaluation of the P24 protein was used 
according to the manufactor’s instruction. Briefly, 100 µl of conjugate working solution 
1 were mixed with 100 µl of the sample. The predefined positive control was mixed 
with the matrice in a ratio 1:1. The mixture was added to the 96 well plate and was 
incubated for 60 min. at 37 °C. After 5 times washing with a 300 µl washing solution, 
200 µl of prepared conjugate working solution 2 was added and incubated for 30 min 
at 37 °C. After the next round of washing, 200 µl of substrate was added and 
incubated for 30 min. at Rt. Finally, 50 µl of stop-solution were added and the 
OD450nm was measured using Elisa Reader Asys Expert Plus (Asys Hiteck).  
2.2.4.6 Concentration of HCV pseudoparticles by ultracentrifugation  
The supernatant of transfected 293T cells containing the HCVpp was layered on 5 ml 
of 20 % (w/v) sucrose and centrifuged in rotor SW40 for 2.30 h at 28.000 rpm at 4 °C. 
The supernatant was discarded, the pellet was dissolved in 30 µl 2x Laemmli buffer 
and used for SDS-PAGE (2.3.4.2) followed by immonodetection (2.3.4.3). 
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3 Results 
3.1 Evolution of the HCV genome 
3.1.1 Generation of HCV AD78-E1/E2 clones in pCR4-Topo 
To evaluate the evolution of the HCV genome in patients infected by contaminated 
AD-globulin, nine patients, who received the batch 8 of contaminated AD-globulin, 
were chosen (Table 2.1.). Serum samples collected at different time points of 
infection (Fig.3.7.) were used. Five of these patients have not been treated with  
IFN-, in three patients, who received the IFN-ribavirin therapy, serum samples for 
analysis have been obtained before initiation of the therapy, and in one  
non-responder patient (patient X) serum sample was obtained 3 years after the 
cessation of the therapy. For seven patients serum samples collected 20 years after 
infection were used. For two patients (patients T and H) serial serum samples 
collected 16, 20, and 28 years p.i. were available for analysis (Fig.3.7.). In parallel, 
globulin batches 8, 10, and 12 were also used as a source of HCV RNA. The 
extracted HCV RNA was used for DNA amplification in a nested - pcr reaction using 
the primers derived from the terminal part of the core gene and terminal part of the 
E2 gene. The primers used for the second round of PCR contained the EcoRV sites 
for a subsequent recloning into the expressing vector. Serum samples from some 
patients have been frozen and thawed during the storage a number of times. Due to 
degradation of HCV RNA in these samples amplification of the HCV envelope genes 
were done in two or four overlapping fragments, which were re-assembled into 
complete envelope sequences upon the results of sequencing of these shorter 
fragments.  
As a result of selective pressure driven by the host HCV circulates in patients as a 
population of particles with closely related but slightly different genomes 
(quasispecies). Therefore, to obtain the major quasispecies variants, the amplified 
E1/E2 fragments were cloned into the vector pCR4-Topo. After transformation into 
the Top10 cells, at least 5 clones of each fragment were picked up and the DNA was 
isolated. Insertion of the E1/E2 fragment was confirmed by gel electrophoresis using 
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 the EcoRV restriction (Fig.3.1). As expected, the E1/E2 fragment, amplified in one 
fragment, showed the correct size of about 1.7 Kb. An example of one E1/E2 
fragment inserted in the pCR4-TOPO vector is attached as a vectorcard  
(Appendix Fig.8.1.). Finally, 1200 ng of DNA was used for sequencing.  
 
Fig.3.1. Cloning of AD78- E1/E2 DNA fragments into the intermediate plasmid pCR4-TOPO 
RNA was extracted from serum samples. E1/E2 DNA fragments were then generated by reverse 
transcription and amplification using the primers sv655s and sv656as, which contained the EcoRV 
sites. The DNA fragments were cloned into the pCR4-TOPO vector and transformed into the Top10 
cells. At least 5 positive clones, after control restriction with EcoRV, were used for sequencing. 
3.1.2 Analysis of the E1/E2 sequences from the contaminated immunoglobulin 
and infected patients 
The first stage of the study assumed the analysis of the HCV envelope genes 
sequences from the contaminated anti-D globulin (this work has been done in 
collaboration with Prof. E. Schreier, Berlin). The E1/E2 sequences were amplified 
from globulin batches Gl8, Gl10, and Gl12. The amplified DNA from batches Gl10 
and Gl12 were used for direct sequencing. The DNA fragments obtained from batch 
Gl8 were further cloned into pCR4-TOPO plasmid and 29 clones were obtained and 
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 sequenced. Both clonal and direct E1/E2 sequences from the anti-D globulin batches 
were subjected to a phylogenetic analysis using the PHYLIP package to evaluate an 
evolutionary relationship between these sequences. As expected, the anti-D 
sequences were clearly separated from E1/E2 sequences of HCV 1b strains 
randomly chosen from the geneBank (Fig.3.4.). At the same time, the analysis 
demonstrated clear separation of the anti-D sequences into two distinct clusters 
(Fig.3.2.) illustrating the position of individual anti-D E1/E2 sequences from batches 
Gl8, Gl10, and Gl12 in a rooted neighbour-joining consensus tree. As can be seen, 
the results have demonstrated presence in the contaminated globulin batch Gl8 of 
two distinct sequence variants, reffered to as Gl8/A and Gl8/B. The separation of 
sequences into two clades was supported with high bootstrap value of 99. The E1/E2 
sequences from the globulin batches Gl10 and Gl12 obtained after the direct 
sequencing of the amplified E1/E2 genes clustered together with the sequences of 
the Gl8-B variant. 
 
Fig.3.2. Consensus neighbour joining tree of the E1/E2 sequences obtained from HCV AD78 
contaminated globulin batches Gl8, Gl10, and Gl12 
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 Phylogenetic analysis of AD78 E1/E2 sequences from globulin batches 8, 10 and 12 was performed 
using the PHYLIP package. Clonal sequences from batches G8-A and G8-B are indicated in red and 
blue, correspondingly. The positions of the E1/E2 sequences obtained from batches Gl10 and Gl12 by 
direct sequencing are marked with green arrows. Bootstrap values for the observed clusters indicated 
in black. The sequence of a randomly chosen HCV 1b isolate (accession number AB008441) was 
used to outgroup the tree. 
To confirm the heterogeneity of the HCV AD78 strain in the contaminated anti-D 
globulin we have amplified the NS3 gene sequences obtained from globulin batches 
Gl8 and Gl12 and from individual AD78-infected patients (this work was done in 
collaboration with Dr. J.Timm and M. Ruhl). Upon a phylogenetic analysis, these 
sequences fell into three clusters clearly separated from randomly chosen  
NS3 sequences from the HCV 1b strains available in the GenBank (Fig.3.3.). 
Reliability of these clades was highly supported by bootstrap analysis. Thus, the HCV 
AD78 strain in contaminated anti-D globulin is not homogeneous and is represented 
by at least three closely related virus variants.  
0.0080
HCV 1b (GeneBank)
Variant A
Variant B
Variant C
 
Fig.3.3. Consensus Neighbour-joining tree of NS3 gene sequences obtained from HCV AD78-
contaminated globulin 8 and 12, AD-infected patients and HCV 1b strains 
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 There are three NS3 sequence variants present in the NS3 sequences observed by direct sequencing: 
A (green), B (dark red), C (blue). The clonal NS3 sequences of the globulin 8 are indicated in orange 
and of globulin 12 in violet, respectively. HCV 1b NS3 sequences from the HCV GeneBank are 
indicated in black. (Obtained in collaboration with Dr. J.Timm and M. Ruhl) 
To analyse the evolutionary relationship between the E1/E2 sequence from the 
contaminated globulin and infected patients the PHYLIP package was used. The 
consensus neighbour-joining tree (Fig.3.4.) included 20 clonal E1/E2 sequences from 
the contaminated globulin, 5 clonal sequences obtained from serum of each infected 
patient collected at different time points, and, additionally, the E1/E2 genotype 1b 
sequences randomly chosen from the HCV Los Alamos database. The results 
demonstrated the clear separation of HCV AD78 sequences from the bulk of HCV 1b 
sequences indicating the evolutionary relatedness of the viruses present in the 
globulin and individual patients. These results confirmed that the anti-D outbreak 
under study was indeed a single source outbreak caused by a single virus strain 
(HCV AD78). Interestingly, the sequences both from the globulin and individual 
patients formed two separate clusters, corresponding to two virus variants (A and B) 
identified in the contaminated globulin batches (Fig.3.2.). These data suggest that 
two observed clades represent two evolutionary lineages that originated from two 
closely related but still distinct viruses already present in the contaminated anti-D 
globulin. This conclusion was further supported by a phylogenetic analysis of 
separate E1 and E2 sequences (Fig.3.5. and 3.6.). Neighbour-joining trees for these 
genes have the same topology as the tree for the E1/E2 region thus confirming the 
fact that the AD78 outbreak was caused by two closely related virus variants already 
present in the infectious source.  
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Fig.3.4. Consensus neighbour-joining tree of the envelope gene sequences obtained from HCV 
AD78-contaminated globulin, AD78-infected patients and HCV 1b strains 
Sequences from HCV1b strains are separated from the bulk of AD78 sequences. Sequences from the 
anti-D globulin and anti-D patients form two distinct clusters. The bootstrap values of the 
corresponding nodes are indicated.  
 
Fig.3.5. Consensus neighbour joining tree of the E1 sequences obtained from HCV AD78-
contaminated globulin batch 8, AD78-infected patients and HCV 1b strains 
Sequences from HCV1b strains are separated from the bulk of AD78 sequences. Sequences from the 
anti-D globulin and anti-D patients fell into two distinct clades. The bootstrap values of the 
corresponding nodes are indicated.  
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Fig.3.6. Consensus neighbour-joining tree of the E2 sequences obtained from HCV AD78-
contaminated globulin batch 8, AD78-infected patients and HCV 1b strains 
Sequences from HCV1b strains are separated from the bulk of AD78 sequences. Sequences from the 
anti-D globulin and anti-D patients fell into two distinct clades. The bootstrap values of the 
corresponding nodes are indicated.  
The planned study of the evolutionary rates of the HCV envelope gene sequences in 
anti-D cohort was possible only by matching the AD78 virus variants circulating in 
each patient with the virus variant present in the contaminated source. Phylogenetic 
analysis of the E1/E2 sequences described above allowed for the identification of 
individual patients infected either with HCV AD78 variants A or B present in the 
globulin batch Gl8 (referred to as Gl8/A or Gl8/B virus variants throughout the thesis). 
Serum samples from 3 patients infected with HCV AD78 variant Gl8/A (patients T, N, 
and Z) and 6 patients infected with variant Gl8B (patients H, X, B, J, M, and Y) were 
available for the study (Fig.3.7.). 
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Fig.3.7. Selection of patient’s serum samples for amplification of the E1/E2 sequences 
Sequences were amplified in two (E1/E2) or one (Env) fragments at indicated time points and cloned 
into the intermediate vector (pCR4-TOPO). Five clones for each sample were sequenced and used for 
further experiments. 
Serum samples collected in 1998-2000, namely about 20 years after infection, from 
all 9 patients were used for amplification, cloning in intermediate pCR4-TOPO 
plasmid, and sequencing of the resulting clones. In addition, amplification of the 
E1/E2 region was performed from serial serum samples of patients T and H collected 
approximately 10-12, 16, and 28 years after infection. Alignment of the resulting 
sequences of the E1 and E2 genome regions presented as supplementary figures 
8.2. and 8.3. (see the Appendix).  
Generation of the clonal sequences from anti-D globulin and these 9 patients allowed 
proceeding to the next stages of the project - analysis of the evolutionary rates of the 
E1/E2 genes of HCV and analysis of the evolution of the humoral immune response 
to HCV envelope proteins in chronically infected individuals. 
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Pat. B E1/E2
Pat. J E1/E2
Pat. M E1/E2
Pat. Y E1/E2
1978 1988-90 1998-90 2006-08
Globulin 8
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1994-95
Pat. T E1/E2          E1/E2              Env Env
Pat. N E1/E2
Pat. Z E1/E2
Selection of the AD-samples 
 58 
3 Results 
 3.1.3 Evolution of the HCV E1/E2 sequences in a group of chronically infected 
anti-D patients 
3.1.3.1 HCV AD78 evolutionary rates in different patients 
The obtained clonal sequences were used for the evaluation of the evolutionary rates 
for the E1 and E2 genes in anti-D chronically infected patients (Tab.3.1).The rates for 
the HCV AD78 isolates tested varied from 0.83 x 10-3 to 4.1 x 10-3 and from  
2.02 x 10-3 to 3.62 x 10-3 nucleotide substitutions per site per year for E1 and E2 
genes, correspondingly. There was no statistically significant difference in 
evolutionary rates of envelope genes of isolates from patients infected with variants 
Gl8/A or Gl8/B of HCV AD78. At the same time, both for patient T and patient H a 
tendency for a decline of substitution rates with duration of HCV persistence was 
noted for the E1 as well as for the E2 genes (Fig.3.8. A, B). 
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 Tab.3.1. Evolutionary rates of the E1 and E2 genes of HCV AD78 variants in different patients 
Variant Gl8 - patient Duration of HCV persistence 
Mean evol.rate (E1 gene) 
(ntsubstitution/site/year) 
(x 10-3) 
Gl8/A-T 
 
 
 
 
Gl8/B-H 
 
 
 
 
Gl8/A-N 
Gl8/A-Z 
Gl8/B-B 
Gl8/B-J 
Gl8/B-M 
11 
17 
20 
28 
 
11 
16 
20 
28 
 
20 
20 
20 
20 
17 
1,95 ± 0,6 
1,06 ± 0,1 
0,97 ± 0,1 
1,1 
 
4,1 
1,842 ± 0,1 
1,87 ± 0,3 
1,08 ±0,1 
 
1,24 ± 0,2 
1,02 
1,24 
0,83 ± 0,1 
2,86 ± 0,16 
Gl8/B-X 20 1,334 ± 0,6 
Gl8/B-Y 20 1,12 
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Variant Gl8 - patient Duration of HCV persistence 
Mean evol.rate (E2 gene) 
(ntsubstitution/site/year) 
(x 10-3) 
Gl8/A-T 
 
 
 
 
Gl8/B-H 
 
 
 
 
Gl8/A-N 
Gl8/A-Z 
Gl8/B-B 
Gl8/B-J 
Gl8/B-M 
11 
17 
20 
28 
 
11 
16 
20 
28 
 
20 
20 
20 
20 
17 
3,16 ± 0,1 
2,32 
2,34± 0,1 
2,02 ± 0,18 
 
3,62 ± 0,3 
3,04 ±0,2 
2,48 ± 0,1 
2,05 ± 0,1 
 
2,76 ± 0,14 
2,6 ± 0,2 
2,47 ±0,06 
3,12 ± 0,08 
2,97 ± 0,152 
Gl8/B-X 20 2,36 ± 0,06 
Gl8/B-Y 20 2,58 ± 0,02 
 
A 
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 B 
 
Fig.3.8. Evolutionary rates of the envelope genes of AD78 isolates from two chronically 
infected patients 
(A) The mean evolutionary rates of E2 gene for patient H (left graph) and for patient T (right graph). 
(B) The mean evolutionary rates of E1 gene for patient H (left graph) and for patient T (right graph). 
The evolutionary rates (nucleotide substitutions per site per year x 10-3) were calculated on the basis 
of sequences obtained at different time points of infection.  
3.1.3.2 Selective pressure on the E1 and E2 genes of HCV AD78 isolates 
To evaluate the selective pressure for the E1/E2 regions within different  
AD78-patients clusters, the ratio of synonymous (dS) to nonsynonymous (dN) 
nucleotide substitutions was calculated (Fig.3.9.). First, the dS/dN ratio was 
calculated for E1 and E2 for AD78 isolates obtained from patient T (infected with the 
virus variant Gl8/A) and patient H (infected with the variant Gl8/B). The analysis of 
the changes in the dS/dN ratio in the E1/E2 genes from both patients at different time 
points p.i. did not show the presence of a strong positive (dS/dN < 1) selection. Quite 
the opposite, the estimated dS/dN values were higher than 1 suggesting a purifying 
selection. The comparison of the dS/dN ratio for E1 and E2 separately in different 
patients 20 years p.i. has shown an evident variation of this parameter even in the 
absence of a strong positive selection, suggesting that HCV envelope gene evolution 
is a patient-specific process.  
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Fig.3.9. Rates of synonymous to nonsynonymous nucleotide substitutions (dS/dN) for E1/E2 
genes of HCV AD78 isolates obtained from anti-D patients at different time points post 
infection 
The x –axis indicates the virus variant, patient, and the time interval (delta T in years) between the 
date of infection and the date of a sample collection.  
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 3.1.3.3 Distribution of amino acid substitutions in E1/E2 sequences of AD78 
isolates during persistent infection 
Alignment of the clonal HCV E1/E2 sequences from anti-D patients T and H allowed 
the analysis of a pattern of a.a. substitutions during the chronic phase of infection 
(Appendix Fig.8.2. and 8.3. and Fig.3.10.). Only evolutionary meaningful 
substitutions, namely those present in more than 70 % of tested clonal sequences, 
were included into the analysis. In general, in AD78 isolates obtained from both 
patients a higher heterogeneity in the E2 region than in the E1 gene was observed. 
None of the observed mutations occurred in the putative N-linked glycosylation sites. 
In the E1 sequence of patient T, infected with the Gl8/A variant of the virus, two a.a. 
substitutions D>N and G>S at positions 42 and 60 were fixed during the whole period 
of observation, whereas two a.a. substitutions R>L at position 40 and V>I at position 
96 appear only 16 years post infection (p.i) and remain fixed during the whole period 
of subsequent observation. In the sequences obtained at the last time point of follow 
up (28 years p.i.) additional a.a. substitutions appeared at positions 23 (Y>F),  
65 (T>A), 79 (A>V), and 138 (A>T). In the E2 sequence of patient T, eight a.a. 
substitutions at position 65 (V>I), 67 (S>N), 113 (Q>R), 152 (A>E), 195 (L>S),  
198 (N>D), 202 (I>V) and 276 (G>D) were fixed during the whole period of 
observation, whereas only one substitution A>S at position 29 appeared 16 years 
and a second time 28 years p.i..  
In the E1 sequence of patient H, infected with the Gl8/B variant of the virus, four a.a. 
substitutions at positions 42 (D>S), 44 (S>F), 102 (L>F) and 112 (E>D) were fixed 
during the whole period of observation. One a.a. substitution V>M at position 86 only 
appears 11 years post infection and furthermore one a.a. substitution at position  
122 (V>L) only appears 16 years p.i. After 20 years of infection, four a.a. 
substitutions at positions 50 (A>E), 136 (S>A), 157 (V>E) and 186 (L>P) appeared. 
At the last studied time point (28 years p.i.) only one additional a.a. substitution 
appeared at position 182 (I>V). In the E2 sequences of patient H, three a.a. 
substitutions L>I, I>T and S>D at positions 58, 202, and 264 were fixed during the 
whole period of time. An insertion of additional a.a. which also stayed fixed during the 
whole period of time was at positions 199 (N) and 200 (T). Four a.a. substitutions at 
positions 63 (F>L), 68 (F>I), 74 (P>S) and 113 (Q>R) only appeared 12 years p.i, 
whereas two a.a. substitutions at positions 143 (S>F) and 259 (I>V) appeared  
12 years p.i and stayed fixed till 20 years post infection. Furthermore, two a.a. 
 64 
3 Results 
 substitutions appeared once 12 years p.i at positions 113 (Q>R) and 327 (F>V) and a 
second time 28 years p.i. In one case, a.a. substitution appeared at position 65 (A>F) 
only at the time point 12 years p.i. but 28 years p.i. the a.a. A was again substituted 
by T (A>T). In another case, a.a. substitution at position 99 (G>S) appeared 12 years 
p.i. and at the time points 16 years and 20 years p.i. there was a further substitution 
of the a.a. S by D (S>D). At the last time point of follow up (28 years p.i.) a reversion 
of the a.a. D back to S (D>S) was observed at the same position. After 16 years of 
infection, one a.a. substitution N>K at position 55 appeared and whereas another 
a.a. substitution at position (E>R) appears but 20 years p.i. the amino acid R was 
substituted by K (R>K). Twenty years after infection one a.a. substitution appeared at 
position 61 (A>S). Moreover, only one a.a. substitution appeared at postion  
198 (N>S) 28 years p.i.. 
 
Fig.3.10. Sites of AD78 E1E2 sequence variation 
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 HCV viral genome sequences at sequential time points are illustrated. horizontal lines: Forward 
mutations are indicated with bars above and reverse mutations are indicated with bars below the 
horizontal lines that designate the isolate sequences. The length of the bar reflects the occurrence of 
the mutation observed in all clonal sequences (from 7 to 100 %). Second forward substitutions in 
already mutated a.a.residues are indicated with an asterics. 
During the process of viral evolution in chronically infected host the virus has to 
evade a host immune pressure. Mutations in the E1/E2 regions, which are crucial for 
viral entry (e.g. CD81-binding sites) as well as neutralizing Abs-binding sites could 
provide putative regions for viral escape. Therefore, the occurrence and distribution 
of mutations separately in the E1 and in the E2 sequences of the AD78 isolates 
isolated in the current study was analyzed (Tab. 3.2., 3.3. and Fig.3.11.). During the 
course of chronic infection in patient T, infected with virus variant Gl8/A, and patient 
H, infected with virus variant Gl8/B, only a few a.a. substitutions occurred in the E1 
sequences within a time period of 28 years p.i. Furthermore, only up to 25 % of 
mutations arose in regions known to be targeted by human mAbs in the E1 
sequences from patient H, whereas in the E1 sequences of patient T no mutation 
occurred in human mAbs-binding sites during the whole period of time. The same 
tendency was demonstrated for E1 sequences obtained 20 years p.i. from a group of 
other Gl8 infected patients - most a.a. substitutions were observed in regions outside 
of those known to be targeted by human mAbs. 
	A
YEVRNVSGV YHVTNDCSNS SIVYETADMI MHTPGCVPCV REDNSSRCWV ALTPTLAARN
1                                                                                    58
GSVPTTAIRR HVDLLVGAAA FCSAMYVGDL CGSVFLVSQL FTLSPRRHET VQECNCLIYP
59                                                                                   118 
GHVTGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVAG AHWGVLAGLA YYSMVGNWAK
119                                                                                  178
VLIVMLLFAG VDG
179               191
Antibody-binding sites
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B 	A
GGPTRTIGGS QAQTASGLVS MFSVGPSQKI QLINTNGSWH INRTALNCN
3 51
DSLNTGFLAA LFYAHKFNSS GCPERMASCR PIDKFAQGWG PITYAEPGSL
101
DQRPYCWHYA PQPCGIVPAA EVCGPVYCFT PSPVVVGTTD RSGVPTYRWG
151
ENETDVLLLN NTRPPQGNWF GCTWMNTTGF TKTCGGPPCN IGGLGNNXXL
201
ICPTDCFRKH PXXATYTKCG SGPWLTPRCI VDYPYRLWHY PCTVNFTIFK
251
VRMYVGGIEH RLSAACNWTR GERCNLEDRD RSELSPLLLS TTEWQILPCS
301
FTTLPALSTG LIHLHQNIVD VQYLYGIGSV LVSFAIKWEY ILLLFLLLAD
351
ARVCACLWMM L
362
Surface exposed
HVR I
 
Fig.3.11. Localization of the amino acids substitutions observed in the clonal E1 and E2 
sequences of anti-D patients 
The E1 and E2 sequences of the Gl8/B variant of the HCV AD78 are shown. Red and black lines 
indicate positions of known antibody-binding sites and CD81-binding sites. Regions, where amino acid 
substitutions in the AD78-derived sequences from patients were observed, are shown in green. 
In the E2 sequences the number of newly arising mutations varied depending on the 
phase of infection (Tab.3.3.). As has already been indicated, a tendency for a decline 
of nucleotide substitution rate with duration of HCV persistence was noted for the E1 
as well as for the E2 genes (Fig.3.8. A, B). For the virus persisting in patient T the 
highest number of a.a. substititions was found in the E2 sequnces obtained at the 
first sampling date (1989) indicating that most of the mutations arose during the 
acute/early chronic phase of infection (first 11 years p.i.). About half of these 
mutations occurred in CD-81- or human mAbs-binding sites. During the next years of 
HCV persistence the E2 protein of the virus circulating in patient T remained 
remarkably stable and few newly appeared mutations occurred mainly in the  
CD-81-binding sites. A different dynamic of a.a. substitutions was observed for the 
E2 sequences obtained from serial samples of patient H. In this patient, persistence 
of HCV AD78 was accompanied by a more or less continuous accumulation of 
mutations throughout the whole folow up period. At that, at each sampling point from 
39 to 73 % of newly arising a.a. substitutions in the E2 protein occurred in the CD-81 
and human mAb-binding sites. Analysis of the mutations in the E2 proteins of AD78 
isolates obtained from seven other AD patients 20 years p.i. (Tab.3.3.) demonstrated 
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 that a significant number of a.a. substitutions (36 o 56 %) present were also localized 
within described CD-81 binding sites or regions targeted by human mAbs. 
Tab.3.2. Occurrence and distribution of mutations in the E1 sequences of AD78 isolates 
AD78 
isolates 
number of 
new 
mutations 
 of 
mutations 
human 
mAbs –
binding 
sites 
Outside of 
known 
functional 
sites  
  
        
Gl8/B-H-11 8 8 0 (0 %) 8 (100 %) 
  
        
Gl8/B-H-16 1 9 1 (11.1 %)  8 (88 %) 
          
Gl8/B-H-20 7 16 1 (14.3 %) 6 (85.7 %) 
  
        
Gl8/B-H-26 4 20 1 (25 %) 3 (75 %) 
          
Gl8/B-M-20 12 12 4 (33.3 %) 8 (66.6 %) 
  
        
Gl8/B-B-20 2 2 1 (50 %) 1 (50 %) 
          
Gl8/B-X-20 12 12 0 (0 %) 12 (100 %) 
          
Gl8/B-J-20 2 2 0 (0 %) 2 (100 %) 
          
Gl8/B-Y-20 5 5 1 (20 %) 4 (80 %) 
          
Gl8/A-T-11 1 1 0 (0 %) 1 (100 %) 
          
Gl8/A-T-16 2 3 0 (0 %) 2 (100 %) 
          
Gl8/A-T-20 0 3 0 (0 %) 0 (0 %) 
          
Gl8/A-T-26 3 6 0 (0 %) 3 (100 %) 
          
Gl8/A-N-20 8 8 2 (25 %) 6 (75 %) 
          
Gl8/A-Z-20 3 3 1 (33.3 %) 2 (66.6 %) 
Abbreviations: AD78 isolate – virus variant-patient-years p.i 
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 Tab.3.3. Occurrence and distribution of mutation in the E2 sequences of AD78 isolates 
AD78 
isolates 
New 
mutations 
in the 
whole E2* 
New 
mutations 
in the 
HVR I* 
 of 
mutations 
new mutations 
 in CD81-
binding sites 
human 
 mAbs 
Outside of 
known 
functional 
sites  
  
  
 
        
Gl8/B-H-12 23 9 (39 %) 23 9 (39 %) 0 (0 %) 14 (61 %) 
  
  
 
        
Gl8/B-H-16 27 15 (56 %) 50 14 (52 %) 1 (4 %) 12 (44 %) 
    
 
        
Gl8/B-H-20 15 12 (80 %) 65 11 (73 %) 0 4 (27 %) 
  
  
 
        
Gl8/B-H-26 21 11 (52 %) 86 12 (57 %) 0 9 (43 %) 
    
 
        
Gl8/B-M-20 30 9 (30 %) 30 16 (53 %) 1 (3 %) 13 (44 %) 
  
  
 
        
Gl8/B-B-20 28 12 (43 %) 28 14 (50 %) 1 (4 %) 13 (46 %) 
    
 
        
Gl8/B-X-20 27 11 (41 %) 27 11 (41 %) 0 (0 %) 16 (59 %) 
    
 
        
Gl8/B-J-20 27 12 (45 %) 27 9 (33.3 %) 1 (3.7 %) 17 (63 %) 
    
 
        
Gl8/B-Y-20 25  25 9 (36 %) 0 (0 %) 16 (64 %) 
    
 
        
Gl8/A-T-11 18 10 (55 %) 18 9 (50 %) 1 (5.5 %) 8 (44.5 %) 
    
 
        
Gl8/A-T-17 7 7 (100 %) 25 6 (85 %) 0 (0 %) 1 (15 %) 
    
 
        
Gl8/A-T-20 2 2 (100 %) 27 2 (100 %) 0 (0 %) 0 (0 %) 
    
 
        
Gl8/A-T-26 2 2 (100 %) 29 2 (100 %) 0 (0 %) 0 (0 %) 
    
 
        
Gl8/A-N-20 26 12 (46 %) 26 8 (32 %) 2 (7.3 %) 16 (61.7%) 
    
 
        
Gl8/A-Z-20 31 12 (39 %) 31 11 (35.4 %) 1 (3.2 %) 19 (61.4%) 
Abbreviations: AD78 isolate – virus variant-patient-years p.i. 
* New mutations in the whole E2 in the HVR I include the reverse mutations to the consensus  
 globulin 8 sequence 
3.1.3.4 Rate of forward and reverse mutations in the HCV AD78 E1/E2 
sequences from patient H and patient T 
It is often assumed that evolution of HCV is driven on the one hand by immune 
pressure, which evidences in appearance of the “forward” or escape mutations, and 
on the other hand by structural and/or functional constraints, which manifests 
themselves in sequence preservation or reversion of sequences toward consensus. 
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 In order to assess a possible contribution of structural and functional constrains to 
HCV evolution in chronically infected individuals we investigated the direction of 
sequence mutations the E1/E2 sequences from patient T, infected with virus variant 
Gl8/A, and from patient H, infected with virus variant Gl8/B. The mutations observed 
in the sequences obtained from patients T and H at different time point p.i. were 
divided into two groups depending on the time period of infection. Group one  
(Gl8/A-T-78-89 and Gl8/B-H-78-89) included the mutations observed in the E1/E2 
sequences obtained from each patient at the fist sampling time point (covers the first 
11 years of acute and chronic infection). The second group (Gl8/A-T-89-06 and 
Gl8/B-H-89-06) included the mutations, which were detected in the sequences 
obtained during the subsequent sampling time points and reflected the changes 
occuring during the late phase of chronic infection (subsequent 17 years of infection) 
(Fig.3.12.). A number of forward (mutations away from HCV 1b consensus 
sequence) or reverse (mutations toward the 1b consensus sequence) mutations was 
calculated. In sequences evolving during the first 11 years p.i. (time period spanning 
the acute phase of infection and early chronic phase) 13 of 21 a.a. substitutions in 
the E1E2 sequences from patient H were considered as forward (65 %) and  
7 substitutions (35 %) as reverse mutations to the HCV 1b consensus sequence. In 
the late phase of chronic infection (covering the period between 11 and 28 years p.i.) 
similar levels of forward (52 %) and reverse mutations (48 %) was noted. For patient 
T forward mutations constituted 50 of a.a. substitutions occurred during the first  
11 years p.i. During the late phase of chronic infection 5 of 6 arosed mutations  
(83 %) evolved away from the consensus sequence and only 1 mutation (17 %) 
reverted back to consensus sequence. 
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Fig.3.12. Forward and reverse mutations accumulated in E1/E2 sequences of HCV AD78 
isolates from patients T and H during two periods of infection – 1978-1989 (first 11 years of 
infection) and 1989-2006 (subsequent 17 years of infection) 
Total number mutations equal to 100 %. 
3.2 Analysis of HCV-specific humoral immune responses in AD78-patients 
3.2.1 Preparation of the plasmids expressing the envelope proteins of the HCV 
AD78 isolates 
The E1/E2 clonal sequences amplified from the contaminated globulin batch Gl8 and 
from patient’s T and H serum samples collected at different time points, as has been 
indicated above, were cloned into the intermediate pCR4-TOPO plasmids. Clonal 
sequences for each AD78 isolate were used to create a set of “consensus” 
sequences for each group of these clones. That allowed the identification of clones 
with minimal number of a.a. substitutions in comparison to these “consensus” 
sequences. All these clones were used in the next stage of the project for recloning 
of the E1/E2 sequences using the EcoRV sites into the expressing plasmid phCMV-
IRES according to the protocol described in the “Material and Methods” section. 
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 3.2.2 Generation of artificial HVRI variants and their insertion into the 
expression plasmid phCMV-IRES 
Previous studies have shown that HCV nAbs are directed not only against epitopes 
within the HVRI but also against epitopes located outside of this region. One of the 
aims of our study was the analysis of the evolution of the HCV envelope-specific 
humoral immune response. This task could be facilitated by availability of a tool, 
which would allow differentiating between antibodies reacting with the epitopes 
located inside and outside of the hypervariable region I. To generate such a tool, a 
set of four artificial variants of HVRI was designed (Fig.3.13.).  
During the design procedure an attempt was made to preserve the conservative a.a. 
residues present in all known HVRI sequences, as well as to keep at least some of 
the basic a.a. residues (R, H, and K) presumably important for HCV infectivity. We 
assumed that this approach might have led to a generation of a HVRI variant that 
could preserve the secondary structure of the E2 protein and would not be 
immunologically active. The peptides corresponding to the designed artificial HVRI 
variants (AD-M6 to AD-M9) were synthesized and their reactivity in ELISA with sera 
from anti-D patients were compared with that of the peptides corresponding to the 
natural HVRI sequences of the AD78 variants Gl8/A, Gl8/B, and HVRI from the AD78 
consensus sequence (Fig.3.13.). As expected, the peptides with naturally occurring 
sequences reacted with the majority (69-80 %) of anti-D sera. In contrast, the 
peptides with artificial sequences demonstrated much less reactivity. For subsequent 
experiments the variants M8 and M9, which reacted correspondingly with 4 % and 
none of the anti-D sera, were chosen. Corresponding oligonucleotides containing the 
SalI and PsiI restriction sites were synthesized and used for swapping the natural 
HVRI fragments within the envelope gene sequence of AD78 variants Gl8/A and 
Gl8/B were cloned into the intermediate pCR4-TOPO vector. The SalI restriction site 
(pos. 570 bp in the E1 sequence) upstream of the HVRI in the sequence of Gl8/A or 
PsiI restriction site (pos. 680 bp in the E2 sequence) downstream the HVRI in the 
sequence of Gl8/B were generated by site-directed mutagenesis (SDM). These sites 
were used for exchange of the natural HVRI fragments in Gl8/A and Gl8/B 
sequences with the artificial variants M8 and M9. Afterwards, the whole E1/E2 
sequences containing the artificial HVRI, were recloned into the expressing plasmid 
phCMV-IRES using the EcoRV restriction sites. The scheme of the cloning procedure 
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 is presented on Fig.3.14. and Fig.3.15.. The generated plasmids were used in the 
series of subsequent experiments for transfection of the 293T cells.  
 
Fig.3.13. Reactivity of HVRI synthetic peptides in ELISA with sera from chronically AD78-
infected patients  
Amino acid residues conserved in all known variants of natural HVRI are indicated in red. Asterics 
marked the position of basic a.a. residues that are assumed to be important for infectivity. 
 
 
Fig.3.14. Position of the SalI and PsiI restriction sites used for insertion of the artificial HVRI 
into the E1/E2 sequence 
Site-directed mutagenesis was used to generate the SalI restriction site in the Gl8/A sequence or the 
PsiI restriction site in the Gl8/B sequence.  
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Fig.3.15. Cloning strategy for generation of plasmids expressing the Gl8/A and Gl8/B E1/E2 
sequences containing the artificial variants of the HVRI (M8 and M9) 
The first step included a generation of the SalI restriction site in the Gl8A sequence or the PsiI 
restriction site in the Gl8B sequence by site-directed mutagenesis (SDM). pCR4-TOPO plasmids 
containing the Gl8/A or Gl8/B sequences with generated restriction sites were used for swapping the 
natural HVRI fragments with the artificial ones. The resulting plasmids were restricted with EcoRV and 
the E1/E2 sequences were ligated into the EcoRV restricted expression vector phCMV-IRES. 
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 3.2.3 Expression of a full length E1/E2 heterodimer in 293T cells 
Studies of the reactivity of the envelope antigen with sera from different patients 
required expression of the full length E1/E2 heterodimers. Therefore, the 293T cells 
were transfected with the expression vector phCMV-IRES containing the E1/E2 
sequences from AD78 isolates, including the wt, M8 or M9 variant sequences  
(see 3.2.1.). To see if the transfection led to the expression of the desired proteins, 
the cell lysates were subjected to SDS-PAGE under denaturating conditions. The 
proteins were transferred to the nitrocellulose membrane and immunostained with 
either E1- or E2-specific mouse monoclonal antibodies directed against linear 
epitopes of E1 (a.a. 1-17) or E2 (a.a. 144-180). As expected, Western blot analysis 
demonstrated the presence of polypetides with the molecular weights of 
approximately 30-34 kd and 60-75 kd, which corresponded to E1 and E2 protein 
monomers, respectively, in each of the tested sample of cell lysate (Fig.3.16.). Due to 
a low available amount of the first mouse mAb A4 directed against a linear epitope of 
the E1 protein, the expression of E1 protein could only be confirmed for the virus 
variants of the HCV AD78 Gl8/A isolate.  
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Fig.3.16. Immunodetection of HCV AD78 E1 and E2 proteins expressed in 293T cells 
Cell lysates of the 293T cells transfected with the expression vector phCMV-IRES encoding the E1/E2 
sequences of different HCV AD78 variants were subjected to SDS-PAGE. The proteins were 
transferred to the nitrocellulose membrane and immunostained with mouse monoclonal antibodies to 
E1 (mAb Ab4) (Fig.3.16. A) or to E2 (mAb CET3) (Fig.3.16. B). 
3.2.4 Binding experiments of expressed E1/E2 heterodimer with human sera  
The prepared and analysed 293T cell lysats containing the expressed E1/E2 
heterodimers of HCV AD78 variants, including the original HCV AD78 variants Gl8/A 
and Gl8/B present in the batch 8 of the contaminated globulin, as well as evolving 
AD78 variants obtained from patients T and H infected with these virus variants, were 
used as a source of HCV antigens in binding experiments (immunoenzyme analysis) 
to assess the HCV-specific immunoreactivity reactivity of homologous and 
heterologeous sera from AD78-infected patients. 
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Fig.3.17. Immunoreactivity of the sequential serum samples from HCV AD78-infected patients T 
and H with four different variants of the homologous AD78 E1/E2 heterodimers 
Reactivity of autologous sera with E1/E2 heterodimer was assessed by a solid-phase ELISA. For the 
normalization of antigen (E1/E2) concentration the reactivity with the the mouse mAb CET-3 directed 
at the conserved sequence present in all tested E1/E2 variants was used. Sera were tested at the 
dilution 1: 100. The broken line indicates the cut off value.  
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 (A) Reactivity of sera obtained from patient T in 1988-2008 with four variants of the E1/E2 heterodimer 
corresponding to the original AD78 Gl8/A and variants of the Gl8/A virus present at different time point 
of infection in patient T. (B) Reactivity of sera obtained from patient H in 1988-2006 with four variants 
of the E1/E2 heterodimer corresponding to the original AD78 Gl8/B and variants of the Gl8/B virus 
present at different time point of infection in patient H. 
Availability of the plasmids expressing different variants of the E1/E2 heterodimers 
allowed for an analysis of the influence of the evolutionary changes in the sequences 
of envelope proteins of AD78 isolates on their ability to bind homologous serum 
samples collected at different time points of infection. In the following experiments 
the reactivity of the serum samples from patients T, infected with virus variant Gl8/A, 
and H, infected with virus variant Gl8/B, collected between 1988 and 2008 with Env 
variants corresponding to isolates from the contaminated globulin and from patients 
in 1994/95, 1998, and 2006 were measured (Fig.3.17. A, B). The antigen 
concentration of each antigen was normalized using the mouse mAb CET-3, directed 
against the linear epitope of E2 (a.a. 144-180) conserved in all AD78 isolates, and 
allowed the evaluation of reactivity under the same conditions for each antigen. 
Despite relatively high levels of variability of reactivity of individual sera with different 
antigen a general tendency was noted, according to which the sera collected a 
particular time point reacted better with the E1/E2 antigens collected at earlier time 
points than with those collected at later time points. These data suggested that the 
accumulation of mutations in the E1/E2 sequences during the evolution of the virus in 
chronically infected patients might have influence (reduce) their ability to react with 
the anti-viral antibodies present in infected host at each time point of infection.  
In the next step of the binding studies a question of ability of antisera from patients 
infected with one HCV strain to cross-react with E1/E2 proteins encoded by other 
HCV strains was addressed. The reactivity of sera from 25 HCV AD78 infected 
patients or 25 sera from patients infected with genotype 1b with HCV AD78 E1/E2 
heterodimers from virus variants Gl8/A or Gl8/B was tested by ELISA (Fig.3.18.). The 
result has shown that there was no significant difference in the frequency and level of 
reactivity of sera from patients infected with different subtype 1b HCV strains with two 
antigens used. On the other hand, additional ELISA experiments performed with the 
same virus antigens (E1/E2 heterodimers from virus variants Gl8/A or Gl8/B) 
demonstrated significant difference (p<0.05) in the cross-reactivity of sera from 
patients infected with genotype 1b HCV or from patients infected with other 
genotypes (2 and 3) (Fig.3.19.). 
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Fig.3.18. Cross-reactivity of sera from HCV AD78 infected patients or from patients infected 
with HCV subtype 1b strains with two virus antigens (HCV AD78 E1/E2 heterodimers from virus 
variants Gl8/A or Gl8/B) 
Reactivity of patient’s sera with E1/E2 heterodimers was assessed by a solid-phase ELISA. For the 
normalization of antigen (E1/E2) concentration the reactivity with the the mouse mAb CET-3 directed 
at the conserved sequence present in all tested E1/E2 variants was used. Sera were tested at the 
dilution 1: 100. The broken line indicates the cut off value.  
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Fig.3.19. Cross-reactivity of sera from patients infected with HCV subtype 1b or other HCV 
genotype strains with HCV AD78 E1/E2 heterodimers from virus variants Gl8/A or Gl8/B 
Reactivity of patient’s sera with E1/E2 heterodimers was assessed by a solid-phase ELISA. For the 
normalization of antigen (E1/E2) concentration the reactivity with the the mouse mAb CET-3 directed 
at the conserved sequence present in all tested E1/E2 variants was used. Sera were tested at the 
dilution 1: 100. The broken line indicate the cut off value.  
Among the variants of the Env sequences inserted into the expressing plasmid were 
sequences, in which the natural HVRI sequence was substituted with the artificial 
HVRI variants (M8 or M9). These artificial HVRI sequences have been shown not to 
react with the human antibodies to natural HVRI but theoretically could preserve the 
correct conformation of the E1/E2 heterodimers, as already described. Application of 
such modified version of the E1/E2 heterodimers would allow assessing the anti-Env 
antibodies directed against the epitopes located outside of the HVRI. Therefore, in 
the next experiment we studied the reactivity of sera from HCV AD78 patients with 
Gl8/A variants wt and artificial M8 and M9 variants of HVRI (Fig.3.20.) using the 
ELISA. The results of these experiments have not demonstrated a significant 
difference in the reactivity of sera from HCV AD78 patients with Gl8/A variants  
(wt, M8 and M9). These data suggest that most of the anti-HCV antibodies present in 
HCV patients’ sera are directed against epitopes located outside of the HVRI area.  
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Fig.3.20. Reactivity of sera from HCV AD78 infected patients with HCV AD78 E1/E2 
heterodimers from virus variants Gl8/A (wt, M8, M9) 
Reactivity of 20 patient’s sera with E1/E2 heterodimers was assessed by a solid-phase ELISA. For the 
normalization of antigen (E1/E2) concentration the reactivity with the the mouse mAb CET-3 directed 
at the conserved sequence present in all tested E1/E2 variants was used. Sera were tested at the 
dilution 1: 100. The broken line indicates the cut off value.  
3.2.5 Neutralization of HCV AD78 pseudoparticles by patients sera  
Development of the HCV pseudoparticles system (HCVpp) (Bartosch et al., 2003b) 
made it possible to analyze the HCV-neutralization potentials of human sera. In the 
current study this system was used to analyze reactivity of sera from AD78-infected 
patients with the set of HCV AD78-based pseudoparticles. One of the prerequisites 
for the accurate assessment of the neutralization titre of antibodies is the 
standardization of the quantity of the antigen – in this case, of HCvpp. In all the 
subsequent experiments the quantities of different variants of HCVpp was 
standardized and equalized according to the results of the quantitative determination 
of the p24 (gag) protein, a constituent of pseudoparticles. 
In the first series of experiments ability of sera from different groups of AD patients 
and individuals infected with other HCV 1b strains to neutralize the HCVpp 
expressing the E1/E2 proteins encoded by AD78 Gl8/A and Gl8/B virus variants was 
tested (Fig. 3.21. A, B). HCVpp bearing envelope proteins of virus variants from 
AD78 Gl8/A wt and Gl8/B were neutralized more effectively by sera from patients 
infected with the same virus variant than by sera of patients infected with another 
AD78 Gl8 virus variant. Even less effective in neutralization of the AD78-based 
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 HCVpp were sera from randomely chosen patients infected with other HCV 1b 
strains.  
A              B 
 
 
Fig.3.21. Neutralization of HCVpp bearing envelope proteins of virus variants AD78 Gl8/A and 
Gl8/B by sera of patients infected with Gl8/A, Gl8/B sera or sera from randomely chosen HCV 
1b infected patients 
HCVpp were normalized by P24 quantification. HCVpp were preincubated for one hour with sera 
dilutions before the infection of the Huh7.5.1. cells. The means of neutralization titers (IC50) and 
standard derivations are indicated.  
The next series of experiments were directed at the analysis of the ability of sera 
obtained at different time points of infection from patients T and H to neutralize the 
series of HCVpp, in which the E1/E2 sequences came from the AD78 Gl8/A or Gl8/B 
virus variants and from serum samples collected from these two patients after  
16 (1994), 20 (1989), and 28 (2006) years p.i. The concentrations of different HCVpp 
preparations were equalized according to the results of p24 quantification and the 
infectivity of these HCVpp was tested (Fig.3.22. A, B). As can be seen, the evident 
reduction of HCVpp infectivity corresponding to the duration of infection was 
observed for pseudoparticles bearing the E1/E2 sequences from both patients. Thus, 
the highest infectivity was recorded for HCVpp bearing the envelope proteins 
sequences derived from the viruses present in contaminated globulin (variants Gl8/A 
and Gl8/B). In contrast, the pseudoparticles, which included the E1/E2 sequences 
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 from patients collected at different time points p.i., were much less infectious for 
Huh7.5.1 cells. 
A            B 
 
Fig.3.22. infectivity of HCVpp bearing envelope proteins from the AD78 Gl8/A or Gl8/B virus 
variants and from serum samples collected at different time points p.i. from patients T and H 
The HCVpps were generated on the basis of the E1/E2 sequence of the HCV AD78 virus variant 
Gl8/A, Gl8/B and of serum samples from patient T (A), infected with virus variant Gl8/A, and from 
patient H (B), infected with virus variant Gl8/B. For the evaluation of the infectivity rate, the amount of 
HCVpp was normalized on the basis of P24 quantification. The infectivity of HCVpp bearing the 
envelope proteins of the virus variants Gl8/A (A) or Gl8/B (B) was considered as 100 %. Data of three 
experiments are presented. 
The set of equalized HCVpp bearing the AD78 E1/E2 sequences derived from the 
globulin and patients T and H were used in the neutralization assay. The results of 
these experiments are presented in tables 3.4. and 3.5.. All sera from patient T, 
infected with the HCV AD78 Gl8/A virus variant, irrespective of the sampling date, 
efficiently neutralized the HCVpp bearing the E1/E2 sequence from the original Gl8/A 
virus. The same sera, however, reacted less effectively with HCVpp bearing the 
E1/E2 sequences amplified from patient T in 1994 and 1998, or 16 and 20 years p.i, 
correspondingly indicating that mutations accumulated during this time period 
reduced the ability of HCVpp to bind the neutralizing antibodies. Unexpectedly, all 
tested sera turned out to be very efficient in neutralizing the pseudoparticles that 
included the E1/E2 sequence amplified from the patient sera collected in 2006 or  
28 years p.i.. 
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 A different pattern of neutralization activities was observed in experiments performed 
with the materials and sera obtained from patient H. In this case, all sera, irrespective 
of the time of collection, demonstrated approximately similar levels of neutralization 
activity against HCVpp bearing the E1/E2 sequences derived either from the virus 
Gl8/B present in the globulin or from the patient H at different sampling time points. In 
general, the whole series of neutralization experiments demonstrated no evidence of 
the immune escape. 
Tab.3.4. Neutralization of HCVpp from Gl8/A and patient T from different time points by serial 
autologous sera (geometric mean titres are shown) 
 
 
Tab.3.5. Neutralization of HCVpp from Gl8/B and patient H from different time points by serial 
autologous sera (geometric mean titres are shown) 
 
 
As already has been described in section 3.2., the set of plasmids expressing  
AD78-derived E1/E2 sequences included those, in which the natural HVRI 
sequences were substituted with the artificial HVRI variants (M8 or M9) that did not 
react with the antibodies recognizing naturally occuring HVRI sequences. Cells 
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 transfected with such modified plasmids expressed infectious HCVpp. In a series of 
experiments we tried to assess ability of sera from AD78-infected patients as well as 
of sera from randomly chosen HCV 1b patients to neutralize the HCVpp generated 
on the basis of Gl8/A and Gl8/B envelope sequences, in which the wild type (wt) of 
HVRI was substituted with the M9 variant sequence (Fig.3.23. A, B). The results 
have shown that both variants of HCVpp bearing the M9 sequence (Gl8/A M9 and 
Gl8/B M9) were neutralized much more efficiently by sera from HCV infected 
individuals than HCVpp expressing envelope proteins with naturally occuring HVRI 
variants (Gl8/A wt and Gl8/B wt). This effect was more evident in case of HCVpp 
constructed on the basis of the Gl8/A variant of HCV AD78. 
A               B 
 
Fig.3.23. Neutralization of HCVpp bearing modified (M9) or unmodified (wt) envelope proteins 
of AD78 Gl8/A and Gl8/B virus variants by sera of infected patients 
3.3 Peculiarities of the AD78 E1/E2 sequences 
3.3.1 Presence of additional amino acid stretch at the E1/E2 junction 
Analysis of the E1/E2 sequences from the contaminated globulin and HCV AD78 
infected patients (Appendix Fig.8.2. and Fig.8.3.) have revealed a presence of 
additional 1 to 4 codons at the junction between E1 and E2 genes in most of the  
anti-D sequences. Fig.3.24. and Fig.3.25. demonstrate presence of additional a.a. 
residues encoded by these codons in the E1/E2 sequence of the HCV AD78 variants 
Gl8/A (four residues RGGG) and Gl8/B (two residues GG) obtained from the 
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 contaminated globulin batch Gl8. One additional a.a. residue was found also in one 
of the randomly chosen sequences of the HCV 1b isolates obtained from the HCV 
database (accession number AB016785). 
 
Fig.3.24. Additional amino acid residues at the E1/E2 junction in the sequences of the HCV 
AD78 variants from the contaminated anti-D globulin 
Presence of the additional a.a. residues at the E1/E2 junction raise the question to 
what protein these residues remain fused after the proteolytic processing of the viral 
polyprotein. Comparative analysis of the E1 C-terminal sequences of HCV strains 
from the Los Alamos HCV database, including the signal peptide segment, 
demonstrated absence of any special amino acid substitutions in this area in strains 
bearing the additional amino acid residues (Fig.3.26.). Such a conservation of the E1 
sequences provides a proper processing signal and strongly suggests the invariable 
processing pattern. Thus, despite the absence of direct experimental proof, one 
might reasonably assume that the additional amino acid residues observed at the 
E1/E2 junction just after the cleavage site upon a processing became a part of the  
N-terminal sequence of the E2 protein. 
 
HVRI 
E2 E1 
 86 
3 Results 
 
 
Fig.3.25. Aligment of the HCV AD78 and HCV 1b sequences at the E1/E2 junction 
One additional a.a. residue was also found in one of the randomly chosen sequences of the HCV 1b 
isolates obtained from the EMBL database (accession number AB016785).  
3.3.2 Analysis of the distribution of the additional codons at the E1/E2 
junction in HCV isolates from the GenBank 
Presence of additional codons at the E1/E2 junction in AD78-derived sequences 
raised a question how often such insertions occurred in HCV strains belonging to 
different genotypes and subtypes. Table 3.6. demonstrates the results of the analysis 
of E1/E2 sequences of virus strains included into the Los Alamos HCV database. 
None of the 728 strains of HCV 1a or HCV 3a contains additional codons at the 
E1/E2 junction. In contrast, additional codons were identified in 6 %, 8 %, 0.6 %,  
4.5 %, and 1.2 % of type 1b, 2, 4, 5, and 6 sequences, correspondingly. Of note is 
the fact of variable number of additional codons in sequences of different HCV types. 
Thus, for example, among HCV1b strains we observed from 1 to 4 additional codons, 
while among genotype 2 strains this number varied from 1 to 5 codons. 
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 Tab.3.6. Frequency of additional codons at the 5‘end of HVR I sequences of HCV isolates from 
the HCV Los Alamos database 
 Gt 1a 
(n=728) 
Gt 1b 
(n=1788) 
Gt 2 
(n=809) 
Gt 3 
(n=230) 
Gt 4 
(n=157) 
Gt 5 
(n=88) 
Gt 6 
(n=81) 
1 codon 0 50 14 0 1 2 0 
2 codons 0 9 6 0 0 1 0 
3 codons 0 12 16 0 0 1 1 
4 codons 0 35 0 0 0 0 0 
5 codons 0 0 31 0 0 0 0 
Any 
additional 
codon 
0 106  
(6%) 
67  
(8 %) 
0 1  
(0.6 %) 
4  
(4.5 %) 
1  
(1.2 %) 
 
Identification of additional codons at the E1/E2 junction raised some questions. 
Among them, a question of existence of a mechanism of selection of amino acids 
encoded by these codons rose. To answer this question, the analysis of a frequency 
of different classes of a.a. residues at each position of additional a.a. stretches was 
performed. Table 3.7. demonstrates hydropatic character of residues present in 
additional a.a. set located at the N-terminus of HVRI of 173 type 1b and 2 strains. As 
a control, the a.a. composition of proteins from the SWISS-PROT database was 
used. In contrast to the control proteins, the additional a.a. set under investigation 
was characterized by a much higher frequency of neutral (43 % vs. 19 %) and lower 
frequencies of hydrophobic (34 % vs. 47 %) and hydrophilic (23 % vs. 34 %) 
residues.  
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 Tab.3.7. Amino acid composition of the set encoded by additional codons present at the 5’ end 
of HVRI sequences of 173 type 1b and 2 strains 
 
The next approach assumed an analysis of physico-chemical characteristics of 
residues at different positions of additional a.a. stretches located at the N-terminus of 
HVRI of some HCV strains. The tables 3.8, 3.9. and 3.10. demonstrate the frequency 
of different residues at different positions in 106 type 1b, 67 type 2, and 105 AD78-
derived sequences. 
Tab.3.8. Frequency of amino acid residues encoded by additional codons present at the 5’ end 
of 106 subtype 1b HCV isolates from the HCV Los Alamos database 
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 Tab.3.9. Frequency of amino acid residues encoded by additional codons present at the 5’ end 
of 67 subtype 2 HCV isolates from the HCV Los Alamos database 
 
 
Tab.3.10. Frequency of amino acid residues encoded by additional codons present at the 5’ 
end of 105 HVRI clonal sequences from HCV AD78 contaminated globulin and anti-D patients 
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 Results of this analysis have demonstrated a restricted amino acid usage at each of 
the positions with predominance of neutral and hydrophobic residues. Three residues 
- Cys, Trp, and Asp were absent among the additional amino acids. Another 
important characteristic is the predominance of small and flexible residues in these 
stretches, especially at the very N-terminus, as well as the low frequency of Pro and 
large hydrophobic residues. Of interest is a very high frequency of Arg at position  
-4 in anti-D sequences. In contrast, this residue was never present at this position in 
other HCV 1b sequences. Thus, these results provided an evidence for a selection 
for particular residues in particular positions in the additional a.a. stretches located at 
the N-terminus of HVRI sequence. 
Another interesting and important question concerns the stability of this additional 
track of amino acids during the course of HCV infection. Analysis of the E1/E2 
sequences obtained at different time points of infection from two chronic anti-D 
patients (Tab.3.11.) have shown a possibility of two scenarios. In patient T at a 
particular time during the approximately 10 years interval between infection (1978) 
and the first time point of serum samples collection (1989) a change of the additional 
a.a. stretch from RGGG to HGG occurred. The composition of this HGG track 
remained stable during the rest of the observation period (1989-2006). In patient H, 
however, quite different chain of events has been observed with regard to evolution 
of the additional a.a. stretch. Significant changes in the length and composition of this 
stretch was observed at each time point of observation. Even more so, in contrast to 
situation with patient T, in patient H a variability of the composition of this track at 
particular time points was documented. Thus, the additional a.a. stretches at the  
N-terminus of HVRI are subjected to change and do not always remain stable in the 
course of infection. 
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 Tab.3.11. Additional a.a. residues at the N-terminus of HVRI at different time points of infection 
 
HCV AD78 Gl8 variants  
in the inoculum 
 
 
 
1989 
 
1994 
 
1998 
 
 
 
 
 
 
2006 
 
RGGG 
 
 
Patient T 
 
 - HGG 
 
 - HGG 
 
 - HGG 
 
 
 
 
 
 
 - HGG 
 
GG 
 
 
Patient H 
  
 -S 
 
TSW 
 
MSV 
MSG 
MSW 
MSC 
ASA 
TFC 
 
-ASA  
- - AS 
 
3.3.3 Influence of additional a.a. sequences at the N-terminus of E2 protein on 
HCVpp infectivity  
The revealed restriction on physico-chemical characteristics of a.a. residues at each 
site of additional a.a. stretches located at the E1/E2 junction suggest that these 
stretches most probably have a particular conformation and/or might influence the 
conformation of HVRI or the E1/ E2 heterodimer. This might lead in turn to the 
changes of infectivity of HCV particles. To address this issue, a set of new E1/E2 
expressing plasmids was created to analyse the influence of additional a.a. stretches 
on infectivity of HCVpp (Tab.3.12.). The phCMV-IRES plasmid expressing the 
envelope gene sequence from HCV AD78 Gl8/A variant was used as a backbone. 
The four additional codons at the 5’ end of HVRI present in this E1/E2 sequence 
were modified by replacing them with a natural or artificial a.a. stretches (Fig.3.26.).  
The procedure included the following steps. A number of sequence-specific primers 
were used for the amplification of small DNA fragments of the E1/E2 junction. The 
sense primers encoded the 3’end of the Gl8/A E1 gene that included the SalI 
restriction site, the sequence that encoded the variant of additional a.a. residues, and 
the sequence corresponding to the first 20 nucleotides of the Gl8/A HVRI. The  
anti-sense primer covered the last 20 nucleotides of the Gl8/A HVRI and  
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 15 subsequent nt containing the PsiI restriction site. This protocol allowed for a 
substitution of the additional codons encoding RGGG, which are present in the Gl8/A 
E1/E2 junction, with a desired variant of additional codons. The generated DNA 
fragments were restricted with SalI and PsiI and ligated into the expression plasmid 
phCMV-IRES-Gl8/A. The prepared constructs were verified by sequencing.  
 
Fig.3.26. Scheme of modification of additional codons located at the E1/E2 junction in the 
phCMV IRES vector plasmid expressing envelope gene sequence of the HCV AD78 Gl8/A 
variant 
Four additional codons in the original Gl8/A sequence (black rectangle) have been replaced by codons 
encoding other variants of additional a.a. track (the whole set is indicated in the Table 3.12.) SalI site 
located before and PsiI site located after the HVRI were used for insertion according to the procedure 
illustrated in Fig.3.15. The corresponding fragments were obtained by PCR with a specially designed 
set of primers covering sequence of Gl8/A HVR I and sequences encoding the additional a.a. 
stretchches. 
The prepared set of plasmids, which encode the E1/E2 sequence of the HCV AD78 
Gl8/A variant without (wt) or with modification of the additional codons at the E1/E2 
junction (Tab.3.12.) was used for transfection of the 293T cells and preparation of the 
HCVpp. The resulting set of pseudoparticles was used in the infectivity assay in the 
Huh7.5.1 cell cultures according to the standard protocol. For the exact comparison 
of HCVpp infectivity, the amount of HCVpp was normalized on the basis of P24 
quantification (Gag). 
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 Tab.3.12. Set of expressing plasmids for the analysis of the influence of additional a.a. streches 
on HCVpp infectivity 
Source of sequence Sequence of additional amino acids 
Gl8/A wt - 
Gl8/A wt – deletion of additional a.a. 
Pat T‘ 98 
Pat B‘ 98 
Consensus of additional a.a. from HCV 1b 
sequence set 
Consensus of additional a.a. from HCV 2 
sequnce set 
 
Artificial sequence 
Residues that are never or exceptionally rare 
present in the additional a.a. stretches 
RGGG 
---- 
-HGG 
-SAR 
SGQL 
 
TSSHV 
 
 
GGGGG 
DNDN 
 
 
 
Fig.3.27. Influence of additional amino acid residues at the N-terminus of HVRI on infectivity of 
HCVpp in Huh 7.5.1. cells 
The HCVpps were generated on the basis of the E1/E2 sequence of the HCV AD78 Gl8/A variant 
(Gl8/A-wt). (A) The set of modified HCVpp was created by deletion or substitution of codons encoding 
the four additional amino acids RGGG in the Gl8/A-wt/Env sequence either with naturally occuring or 
artificial codons. (B) For the evaluation of the infectivity rate, the amount of HCVpp was normalized on 
the basis of P24 quantification. The infectivity of HCVpp with deleted additional a.a. residues was 
considered as 100 %. Data of four experiments are presented. 
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 As shown in Tab.3.6. 94 % of the HCV 1b sequences available in the Los Alamos 
database do not contain the insertion of additional a.a. at the N-terminus of the HVRI. 
Therefore, the infectivity of HCVpp with deleted additional a.a. residues was 
considered as 100 % (Fig.3.27.). Comparison of the infectivity of generated set of 
HCVpp bearing different variants of additional a.a. tracks have demonstrated that the 
presence of additional a.a. track in all cases but one (insertion of DNDN) resulted in 
increase of infectivity. The most significant increase (P=0.0335) of approximately  
2,5 folds, however, was observed with the wild type Gl8/A sequence, in which the 
additional track RGGG was present. Increase of infectivity observed for HCVpp 
containing the E12/E2 sequences with other variants of additional a.a. residue was 
not significant, although a statistical trend was noted. Of note is the fact that the 
presence of additional a.a. residues which are never (D) or exceptionally rarely (N) 
present in the context of additional a.a. stretches HCV E2 (variant DNDN) leads to a 
significant decrease in infectivity of HCVpp (P=0.0008). 
3.3.4 Influence on HCVpp infectivity by interaction of additional a.a. at the  
N-terminus of E2 with HDL 
Recently, an enhancement of HCVpp infectivity by human high-density lipoprotein 
(HDL) and involvement of HVRI into this process was described (Bartosch et al., 
2005). These results seem logical considering the fact that HDL is a natural ligand of 
SR-BI, one of the receptors involved in mechanisms of HCV entry. Our results 
described above (Fig.3.27.) have demonstrated that presence of additional a.a. track 
at the N-terminus of HVRI might influence the infectivity of HCVpp. One of the 
mechanisms of such increment might be associated with the changes of HVRI 
conformation, which, in turn, might influence the interaction of HCVpp with SR-BI 
through the HDL. To address this issue, the Huh7.5.1. cells were pre-incubated for  
1 h at RT with normal DMEM (Fig.3.28. Step1 on top) as negative control or with 
DMEM containing HDL (10µg/ml) (Fig.3.28. Step1 down). Afterwards, the standard 
infectivity assay was performed using a set of HCVpp described in Tab.3.12. and 
Fig.3.28.. 
Two additional control plasmids, expressing the HCV H77.20 and Gl8/A M9 E1/E2 
sequences, were also used. As it can be seen from Fig.3.29. these experiments, 
however, provided the equivocal results. With several preparations of HCVpp 
containing the variants of additional a.a. tracks RGGG, HGG, TSSHV, and GGGGG, 
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 as well as with the H77-20 HCVpp, an increase of infectivity by HDL was noted. In 
contrast, with preparations of HCVpp containing the variants of additional a.a. tracks 
SAR, SGQL and with the variant of the Gl8/A sequence containing the artificial 
version M9 of HVR1 evident decrease of infectivity was registered. The infection rate 
of HCVpp bearing the artificial a.a. variant DNDN was reduced to minimal values.  
 
Fig.3.28. Schematic presentation of the experiments on analysis of the influence of HDL on 
infectivity of HCVpp with modified variants of additional a.a. stretches at the N-terminus of 
HVRI  
Step 1 - Huh-7.5.1. cells were pre-incubated either with normal DMEM or with DMEM containing HDL 
(10µg/ml). Step 2 - 100 µl of generated HCVpp bearing the natural or artificial a.a. tracks in the Gl8/A 
wt E1/E2 backbone sequence was added and the infection rate was evaluated after 72 h of incubation 
at 37 °C.  
 
 
Fig.3.29. Influence of HDL on infectivity of HCVpp with modified variants of additional a.a. 
stretches at the N-terminus of HVRI 
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The data accumulated during the last years suggest that HCV control and clearance 
during the early phase of infection are associated not only with broad and vigorous 
HCV specific T cell responses (Lechner et al., 2000) but also with induction of virus-
neutralizing antibodies (Pestka et al., 2007). HCV infection in a large number of 
patients, however, progresses to chronicity and the virus might persist for years 
despite a presence of relatively high titers of antiviral antibodies, including those that 
rather efficiently neutralize other HCV isolates (Lavillette et al., 2005; Pestka et al., 
2007). The reasons why these cross-neutralizing antibodies are not able to clear the 
HCV in most of chronically infected individuals remain unclear. In addition, 
organization of distinct B-cell epitopes located in envelope proteins of HCV as well as 
the heterogeneity and natural evolution of these epitopes during the different stages 
of infection, and especially during the chronic phase remains undefined or poorly 
understood. The aim of the current project was to find answers to some of these 
important questions and to get an insight into the role of the humoral immune 
response in control and resolution of HCV infection. Investigations in this field, 
however, usually are hampered due to the fact that investigators have to deal with 
patients infected with different HCV and no information on the ancestral virus 
sequences is available. The essential feature of the current project is the use of a 
special group of patients – women infected with the same HCV strain (AD78) in a 
single-source outbreak. This cohort represents a unique model to study the evolution 
of HCV under the immune selective pressure of the host and to analyze the role of 
different immune responses, including the impact of virus-neutralizing antibodies on 
elimination of the virus from infected patients.  
Analysis of the E1/E2 sequences obtained from the batches 8, 10 and 12 of the 
AD78 HCV-contaminated globulin unexpectedly revealed heterogeneity of the virus 
genome population. The results of the phylogenetic analysis (Fig.3.2.) have shown a 
separation of the sequences into two major clades that was supported by a high 
bootstrap value. Heterogeniety of the HCV virus present in contaminated AD-globulin 
was supported by our data on amplification and analysis of the sequences 
corresponding to the fragment of the NS3 gene (Fig.3.3.), which demonstrated 
division of the sequences into 3 clusters. In sum, these results have clearly 
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 demonstrated simultaneous presence of at least two variants of the HCV in different 
batches of the contaminated AD-globulin. In order to see if this two variants represent 
different strains of HCV or just variants of the same strain we subjected to a 
phylogenetic analysis separately E1 and E2 and the whole envelope sequences 
obtained from the batches of contaminated globulin and from a number of individual 
patients infected with the virus or viruses present in these batches (Fig.3.4, Fig.3.5. 
and Fig.3.6.). The results of these experiments have demonstrated a statistically 
significant separation of HCV AD78 sequences from the bulk of HCV 1b sequences 
obtained from the Los Alamos HCV database indicating: (a) the evolutionary 
relatedness of the viruses present in the globulin and individual patients; (b) that the 
viruses present in the globulin and AD-patients in fact represent different variants of 
the same HCV strain, which is quite different from all other HCV 1b strains. Of 
special importance is the fact that the sequences from both globulin and individual 
patients formed two separate clusters suggesting that these two clades respresent 
two evolutionary lineages that originated from two closely related but still distinct 
viruses already present in the contaminated anti-D globulin. In general, these results 
indicated that the anti-D outbreak under study was indeed a single source outbreak 
caused by two variants (referred to as Gl8/A and Gl8/B) of a single HCV AD78 strain. 
At the moment it is not completely clear why upon an analysis of the envelope region 
a presence of only two variants of HCV AD78 strain was detected in contrast to the 
results of the experiments with the NS3 region, which demonstrated existence of 
three variants of this virus. One possible explanation is that the third virus variant was 
present in the contaminated globulin in a relatively low concentration and only two 
other more abundant virus variants were preferentially amplified by the primer set 
used in the current study. Interestingly, we were not able to detect a simultaneous 
presence of both variants of AD78 strain in any of AD-patients suggesting that 
despite transmission with contaminated globulin of two (or three) virus variants only 
one of these variants was able to cause a persistent infection. These data suggest an 
existence of a selection mechanism, which, probably, is related to a difference in the 
ability of the incoming virus variants to adapt to a particular host. 
The revealed heterogeneiety of the HCV AD78 variants in the contaminated globulin 
and patients meant that the choice of patients for further analysis of HCV evolution 
and humoral immune response was critical. We have checked the phylogenetic 
relatedness of virus isolates in the globulin and individual patients and have identified 
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 a number of matching pairs, including patient T, infected with the Gl8/A variant and 
patient H infected with Gl8/B variant of HCV AD78 (Fig.3.7.).  
Generation of the clonal E1/E2 sequences from the batch 8 of the globulin and 
selected patients allowed the analysis of the envelope genes evolution during the 
long term persistent infection. In general, in all AD78 isolates obtained from AD 
patients a higher heterogeneity in the E2 region than in the E1 gene was observed. 
The mutation rates for the HCV AD78 isolates tested varied from 0.83 x 10-3 to  
4.1 x 10-3 and from 2.02 x 10-3 to 3.62 x 10-3 nucleotide substitutions per site per year 
for E1 and E2 genes, correspondingly. These results are comparable to the 
estimates reported earlier (Smith et al., 1999; Allain et al., 2000; Brown et al., 2005). 
Of note is the fact that both, for patient T and patient H, a tendency for a decline of 
substitution rates in the E1 as well as in the E2 genes with duration of HCV 
persistence was noted. Most probably, this process reflects the fact of a gradual 
adaptation of the virus population to a specific host environment. 
In order to analyze some characteristics of adaptive evolution within the envelope 
genes during the chronic infection the rates of synonymous and non-synonymous 
nucleotide substitution (dS/dN) were estimated. In this study we excluded from the 
analysis the HVRI because data for this most rapidly diverging fragment of the HCV 
genome may result in errornous or misleading interpretation of the general mutation 
rates in the E2 region (McCormack & Clewley, 2002). Analysis of the selective 
pressure for E1 and E2 regions separatly by calculating the average dS/dN ratio for 
AD78 isolates obtained for patient T (infected with the virus variant Gl8A) and patient 
H (infected with the variant Gl8/B) from different time points p.i. did not show a 
presence of a strong positive selection, suggesting that major driving force in the 
HCV evolution during the chronic phase of the infection is a purifying or negative 
selection, which to a significant extent associated with a removal of deleterious 
mutations. The comparison of the dS/dN ratio for E1 and E2 separately in isolates 
obtained from nine AD-patients 20 years p.i. shown evident variation of this 
parameter even in the absence of a strong positive selection, suggesting variability of 
a selection pressure in individual patients. Of note, is a marked variabilty of the 
dS/dN ratio in the the E1 region (Fig.3.9.). Our results have demonstrated a 
significant difference in dS/dN ratios established for patients B and J and those 
estimated for other patients. At the moment, the reason for such a difference it is not 
quite clear. Theoretically, one can not exclude a possibility that virus isolates present 
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 in patients B and J are in fact recombinants of two variants of the AD78 strain. In fact, 
existence of such recombinants in materials of HCV chronic patients has been 
demonstrated (Brown et al., 2005). Our data, however, did not support such a 
supposition because a phylogenetic analysis have demonstrated a consistency in 
topology of the trees constructed separately for the E1 and E2 regions of the AD78 
isolates analysed in the current work. Finally, one shoud mention that in the current 
study an average dN/dS ratio across the E1/E2 region was determined. This 
approach is quite adequate for a comparison of differences in selective pressures on 
HCV envelope genes evolution in different patients. At the same time, as has been 
noted earlier (Sheridan et al., 2004; Brown et al., 2005) this is a highly conservative 
criterion for detecting positive selection, as only a few codons within the HCV 
envelope protein may be under diversifying selection. The signal could therefore be 
diluted in a background of purifying selection, maintained via strong functional or 
structural constraints. As a result, contribution of the diversifying selection to HCV 
envelope evolution might be underestimated. To overcome this problem, future 
studies should involve an estimation of the dN/dS ratio for individual a.a. positions. 
Our preliminary data (performed not in the frame of the current study), however, 
suggested an existence of only a restricted number of sites under positive selection 
(besides those in the HVRI) in the E2 protein of virus isolates obtained from a  
single-source HCV outbreak (Viazov et al., not published). In general, the analysis of 
dN/dS ratio for envelope proteins of AD78 isolates as an indicator of a selective 
pressure on the evolution suggested different dynamic and patterns of HCV evolution 
in individual patients infected with the same HCV strain. 
Other very important and interesting aspects of HCV E1/E2 evolution during chronic 
infection addressed in the current work are the character, localization, and a potential 
functional meaning of a.a. substitutions occured during a long-term virus persitence 
in the infected host. The current investigation included a longitudinal study of a.a. 
substitutions in HCV AD78 Gl8/A- and Gl8/B evolving variants from pateints T and H 
as well as comparative analysis of mutations of virus isolates obtained from nine  
AD-patients at a single time point, namely 20 years p.i. The performed experiments 
revealed a number of general characteristics of HCV E1/E2 evolution during the 
chronic infection. A relatively low number of a.a. substitutions occurred in the E1 
protein (Tab.3.2.), which might be explained by the fact that in the context of the 
E1/E2 heterodimers forming the virion envelope this protein presumably is less 
exposed and accessible to immunocompetent cells. In addition, most of the 
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 mutations observed in this protein were located outside of domains targeted by 
human mAbs. Relatively larger number of a.a. mutations was detected in the E2 
sequences of AD-patients. A significant number of them occurred in known human 
mAbs targeted sites and, especially often, in CD-81-binding sites or, in other words, 
in the functionally relevant domains of the protein (Tab.3.3.). These data indicated 
that in most AD-patients the whole ectodomain of E2 protein and not only the HVRI 
remains under evident selective pressure during the long term chronic infection. 
Theoretically, it is possible that selection pressure on HCV is related to changes in a 
glycosylation pattern. The HCV envelope proteins are highly glycosylated with  
5 to 6 potential N-linked glycosylation sites in E1 and 11 potential sites in E2. Our 
results, however, provided no evidence that HCV long-term persistence leads to 
either loss or acquisition of glycosylation sites. Similar results were reported by 
others (Sheridan et al., 2004).  
Of special interest are our results indicating that significant part of mutations within 
the E2 sequence (around 30 to 80 %) from all patients occurred in HVRI and such a 
tendency remained in patients T and H throughout the whole follow up period 
(Tab.3.3.). Especially demonstrative was a situation with the remarkably slowly 
evolving envelope sequences from patient T, in which all the mutations in the E2 
protein in the period between 17 and 26 years p.i. localized in HVRI. It is assumed 
that HVRI evolution is predominantly driven by the nAb response (von Hahn et al., 
2007; Dowd et al., 2009; Liu et al., 2010). In this context, one should mention our 
data obtained with the E1/E2 variants of env heterodimers in which the natural HVRI 
sequences were substituted with M8/M9 variants that did not react with anti-HVRI 
Abs (Fig.3.20.) These modified E1/E2 heterodimers were able to bind antibodies 
from sera of AD-patients as effectively as the original, unmodified versions of E1/E2 
heterodimers, suggesting that significant fraction of Abs present in patients sera are 
directed against epitopes outside the HVRI. That does not mean, of course, that no 
Abs to HVRI were induced, as presence of such antibodies has already been 
described in numerous publications (Kato et al., 1994; Kato et al., 1993). Future 
studies of sequential sera from patients T and H with a number of specially designed 
HCVpp and HCVcc bearing different variants of HVRI and a set of synthetic peptides 
corresponding to HVRI observed in these patients during the follow-up are planned. 
These experiments should provide an answer to the essential question on 
contribution of specific antibody responses to HVRI to HCV evolution and escape in 
 101 
4 Discussion 
 long term chronic infection. In general, results of the analysis of a.a. substitutions in 
E1/E2 sequences of chronically infected AD-patients complement our data on 
differences in selection pressure in individual patients and clearly indicate that 
evolution of envelope sequences during long term HCV persistence is a  
patient-specific event, which, most probably, is a reflection of differences in genetic 
and physiological background of the corresponding hosts. 
In order to assess a possible contribution of structural and functional constrains to 
HCV evolution in chronically infected individuals we investigated the direction of 
mutations the E1/E2 sequences from patients T and H (Fig.3.12.). In sequences 
evolving during the first 11 years p.i. (acute/early chronic phase) 50 % of a.a. 
substitutions in the E1E2 sequences from patient T and 35 % of substitutions in 
sequences from patient H were considered as reverse mutations to the HCV 1b 
consensus sequence. In the late phase of chronic infection (11 - 28 years p.i.) the 
proportion of the reverse mutation varied in both patients but remained pretty high 
(48 %) in patient H, the HCV sequences from which characterized by a relatively high 
level of evolution, possibly indicating reversion to a more fit viral phenotype in the 
corresponding hosts. In summary, our results complement the most recent data 
obtained for a group of acutely infected individuals (Kuntzen et al., 2007; Liu et al., 
2010) and emphazied a remarkable impact of reversion on intrahost HCV evolution 
envelope proteins. It seems that HCV evolution during the long term chronic phase 
besides being immunologically driven, to a significant extent is limited also by 
structural and/or functional constraints, which manifests themselves in sequence 
preservation or reversion of sequences toward consensus.  
Analysis of the characteristics and localization of mutations in AD cohort has 
demonstrated different pace of evolution in HCV AD78-infected patients T and H. In 
patient H persistent changes in the E1/E2 sequences with approximately similar 
frequency of a.a. substitutions within and outside of known functional sites and 
domains was observed. In contrast, in patient T the number of mutations in the E1/E2 
sequences remained quite low during the whole follow-up and most of the observed 
mutations localized in the HVRI and CD-81-binding sites. The reasons for such a 
dramatic difference are not clear. Patient T demonstrated no evidence of 
immunosupression and serum samples collected from both patients demonstrated 
comparable ability to bind to the homologous and heterologous E1/E2 antigens and 
to neutralize autologous and heterologous HCVpp.  
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 Different trends in the E1/E2 evolution in individual AD-patients observed in the 
current study and manifested in unequal selection pressure, rates, character, and 
patterns of a.a. substitutions raise the question how the resulting mutations in the 
envelope proteins are translated into changes of the properties of the virus and its 
interaction with the infected host during a long term persistance. In general, our data 
are in favor of a supposition that accumulation of mutations over time may incur a 
fitness cost reducing biological properties of the virus in a particular environment. It is 
clear, that a significant number of observed a.a. substitutions, which have been 
located in the HVRI, or in CD81- or human mAb-binding sites, would change an 
ability of the virus to react with cellular receptors and penetrate the intracellular 
pathways. One should also mention that the mutations located outside of known 
functional domains and sites may also significantly influence properties of viral 
particles. Thus, in a recent publication Keck and co-authors (Keck et al., 2009) 
reported that during the chronic phase of HCV infection and in the presence of 
broadly neutralizing serum antibodies, mutations occuring outside receptor binding 
sites resulted in structural changes leading to complete escape from neutralizing 
antibodies, while simultaneously compromising viral fitness by reducing binding to 
CD81. Considering location and number of mutations in our set of AD78-derived 
sequences one might have expected that the HCVpp bearing these sequences would 
demonstrate different properties in the immunological and infectivity tests. Indeed, 
results of the immunobinding experiments, in which ability of HCVpp bearing the 
E1/E2 sequences collected at different time points p.i. from patients T and H to react 
with autologous patient’s sera was asessed, have demonstrated a general tendency. 
According to this tendency, sera collected at a particular time point reacted better 
with E1/E2 antigens collected at earlier time points than with those collected at later 
time points p.i. These data suggested that the accumulation of mutations in the 
E1/E2 sequences during the evolution of the virus in chronically infected patients 
might have reduced their ability to bind the anti-viral antibodies present in infected 
host at each time point of infection. Additional evidence of a dramatic influence of the 
mutations accumulated over time in the viral envelope on HCV phenotype were 
obtained in the experiments on HCVpp infectivity (Fig.3.22.). The pseudoparticles 
generated on the basis of E1/E2 sequences obtained from sequential follow-up 
samples from both patients demonstrated evident reduction of infectivity during the 
long term HCV persistence. These data indicate that adaptation of HCV to the 
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 gradual changing environment during the long term persistence may influence the 
critical stages of the viral replicative cycle, such as virus entry into the cell.  
It is generally assumed that virus population is changed over time due to a 
combination of forces like an immune pressure driven by the host and adaptation to a 
new host environment. This, consequently, might lead to appearance of virus 
variants that escape the antibody-mediated neutralization (Bartosch et al., 2003) 
(Keck et al., 2008). Recently, experimental proofs of this assumption were reported 
(von Hahn et al., 2007). Using the HCVpp system and sequential virus and serum 
samples from a patient infected with the Hutchinson strain of HCV the authors 
demonstrated evidences of a continuous escape of the circulating virus from 
emerging antibodies and suggested that a humoral immune pressure was a major 
driving force for the observed diversity in the envelope sequences. In the current 
study we also tried to assess if the mutations accumulated in the envelope 
sequences during a long term persistence of HCV AD78 isolates in patients T and H 
have some influence not only on infectivity but also on ability of the mutated viruses 
to avoid a specific neutralization. 
At first, an ability of antisera from patients infected with one HCV strain to cross-react 
with E1/E2 proteins encoded by other HCV strains was tested (Fig.3.18.).The result 
has shown that there was no significant difference in the frequency and level of 
reactivity of sera from patients infected with different subtype 1b HCV strains. 
Considering the fact that not all circulating antibodies are the neutralizing ones, a 
neutralization test was performed, which showed that HCVpp bearing envelope 
proteins of virus variants from AD78 Gl8/A and Gl8/B were neutralized more 
effectively by sera from patients infected with the same virus variant than by sera of 
patients infected with another AD78 Gl8 virus variant or even less effectivly by 
HCV1b sera. Thus, similar to previous reports (Lavillette et al., 2005), the antibodies 
present during a chronic phase of infection are able to neutralize the inoculating virus 
more efficiently than heterologous virus strains. 
Interesting and somehow unexpected results were obtained in neutralization 
experiments with HCVpp bearing the M9 artificial variant of HVRI in the context of 
E1/E2 sequences derived from Gl8/A or Gl8/B viruses (Fig.3.23. A, B). Both variants 
of HCVpp bearing the modified envelope sequences (Gl8/A M9 and Gl8/B M9) were 
neutralized much more efficiently by sera from HCV infected individuals than HCVpp 
expressing envelope proteins with naturally occuring HVRI variants. These data 
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 suggested that the natural HVRI somehow masks crucial epitopes important for virus 
neutralization. This observation complement the results of the most recent report, 
which demonstrated that HCVpp lacking the HVRI are much better neutralized by 
mAbs than HCVpp bearing envelope proteins with HVR (Bankwitz et al.). Both these 
sets of data are important for our understanding of the organization of the B-cell 
epitopes of HCV and would have an evident impact on the HCV vaccine 
development efforts in the future. 
A final series of neutralization experiments was performed using the set of HCVpp 
bearing the E1/E2 sequences both from the ancestral Gl8/A and Gl8/B viruses and 
from evolving Gl8/A and Gl8/B virus variants obtained from patients T and H 16 
(1994-95), 20 (1998), and 28 (2006) years p.i.. Sera from the same patients collected 
at different time points of infection were used for neutralization (Tab.3.4 and 
Tab.3.5.). In case of patient T, sera collected at all time points p.i. rather effectively 
neutralized the HCVpp bearing the envelope sequence of the ancestral Gl8/A virus 
variant but were much less effective in blocking the infectivity of pseudoparticles with 
E1/E2 sequences from 16 and 20 p.i. Quite unexpectedly, the HCVpp bearing the 
envelope sequences corresponding to the virus circulating 28 years p.i. were 
effectively neutralized by all tested sera from patient T. The reasons for such marked 
changes in neutralization pattern are not clear. One might suggest, however, that a.a. 
substitutions accumulated by 2006 (28 years p.i.) played a role of compensatory 
mutations, which somehow restored the conformation of the E1/E2 heterodimer. In 
contrast, for patient H no evident differences in ability of sera collected at distinct time 
points to neutralize HCVpp bearing evolving envelope sequences were noted. In 
summary, these experiments provided no evidence that humoral immune response 
lags behind the changes in envelope sequences of the virus circulating in the host at 
a given time point. In other words, our data suggest that the postulated mechanism of 
escape from antibody-mediated neutralization is not operative in all chronic patients. 
Interpretation of the results of HCVpp neutralization experiments would be 
incomplete without referring to recently reported data on HCV employing multiple 
strategies to infect new target cells (Timpe et al., 2008; Witteveldt et al., 2009). It was 
shown that HCV can be transmitted not only via so-called cell-free route by virus 
circulating in the bloodstream but also via direct cell-to-cell contacts. At that, as has 
been indicated by Brimacombe and co-authers (Brimacombe et al., 2010), the 
extracellular forms of HCV are most likely responsible for spread between hosts and 
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 for liver allograft re-infection following transplantation. However, cell-to-cell 
transmission may represent the dominant route of virus dissemination within 
chronically infected individuals. All HCV cell receptors, including the SR-BI, CD-81, 
claudin-1, and occludin are involved in virus cell-to-cell transmission, however, the 
SR-BI has a more prominent role in this infection route. One of most interesting 
features of HCV cell-to-cell transmission is the fact that of all the anti-glycoprotein 
mAbs tested, the anti-HVRI antibody demonstrated the highest neutralization 
potentials (Brimacombe et al., 2010), which, in fact, is not surprising considering that 
HVRI plays a crucial role in HCV entry by interaction with SR-BI. That, in turn, means 
that in vivo HCV can escape the neutralization mediated by anti-HVRI antibodies. In 
the current study we used the HCVpp assay for measuring neutralization properties 
of the whole patient sera. Our data (Fig.3.23. A, B) have shown that sera of  
AD-patients contain relatively high titres of antibodies to AD78 E1/E2 proteins and 
that most or a significant part of these antibodies are directed against epitopes 
located outside of the HVRI. In addition, our results clearly demonstrated very 
intensive rate of mutations of the HVRI sequence in all envelope sequences obtained 
from AD-patients at different time point p.i. Thus, it is quite possible that anti-HVRI 
antibodies response in AD-patients is masked by a more vigorous humoral response 
to other epitopes of envelope proteins. In this case, the experimental approach used 
in the current study and directed at neutralization of virions transmitted via cell-free 
route would not detect the HCV escape from anti-HVRI antibodies, which very 
efficiently neutralize a virus transmitted by a cell-to-cell route. Future studies based 
on the use of HCVcc bearing different variants of HCV AD78-derived E1, E2, and 
HVRI sequences should provide an answer to the essential question if the HCV 
persistence during the chronic infection is associated with the escape of the virus 
directly transmitted from cell to cell from a specific humoral immune response. 
Upon the studies of E1/E2 diversity in HCV AD78-patients an interesting peculiarity 
of the envelope sequences was noted. The sequences of most of the AD78 isolates 
contained additional 1 to 4 codon at the junction between E1 and E2 genes 
(Appendix Fig.8.3.) Conservation of the sequences at the 3’ end of the E1 gene, 
including the signal sequence region, in all of these sequences suggested that the 
processing of the HCV polyprotein was not disrupted and evidenced for these 
additional codons being an integral part of the E2 gene. Further studies of HCV 
sequences retrieved from the Los Alamos database have shown that these additional 
codons were not a hallmark of the AD78 strain, but were also present in 1.2 to 8 % of 
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 HCV strains belonging to genotypes/subtypes 1b, 2, 4, 5, and 6, but not to type 1a 
and 3 viruses. Analysis of the physico-chemical characteristics of a.a. residues 
encoded by the additional codons demonstrated a predominance of neutral and 
hydrophobic residues in most of the positions suggesting that these additional a.a. 
stretches might be oriented toward a hydrophobic E2 protein core, thus, providing for 
additional stability of the HVRI conformation. Predominance of small and flexible 
residues in these stretches might also facilitate the maintaining of the varied 
conformation states of HVRI. Absence in the additional a.a. tracks of Trp and Cys, as 
well as a very low frequency of Pro, namely, the residues that constrain the 
polyprotein conformation, gives evidence for this hypothesis.  
Peculiarities of the physico-chemical characteristics of additional a.a. residues at the 
N-terminus of the E2 protein as well as their occurrence only in some of HCV 
subtypes/genotypes suggest that additional a.a. stretches appeared not by chance 
and that the mechanism of their selection and preservation is operative. That, in turn, 
means that the additional a.a. track at the N-terminus of E2 might have a particular 
functional significance. In the current study we used the HCVpp system to assess a 
possible influence of additional a.a. on virus infectivity. To this end, a set of new 
E1/E2 plasmids, in which the additional a.a. residues at the N-terminus of HVRI were 
swapped with a number of natural or artificial a.a. stretches, was generated and 
tested for infectivity in Huh7.5 cells. These experiments have demonstrated that the 
presence of additional a.a. track in all cases but one (insertion of DNDN, namely, the 
sequences that are never or very rarely present in naturally occuring additional 
tracks) resulted in an increase of infectivity of pseudoparticles (Fig.3.27.) suggesting 
that the viruses bearing E2 proteins with modified N-terminus might also posess 
unique biological properties in vivo. 
The mechanism of formation of the additional a.a. stretches is unknown. Casino and 
co-workers (Casino et al., 1999) have observed an imperfect direct repeat in the 
clonal sequence of one HVRI variant and suggested that a C-terminal region of the 
HVRI was duplicated and replaced the N-terminal region resulting in appearance of 
one extra amino acid residue. However, our analysis of multiple HCV sequences 
retrieved from the Los Alamos database as well as from AD78 sequence dataset did 
not reveal presence of any direct or inverted repeats either in HVRI or in flanking 
sequences of strains bearing additional codons at the 5’ terminus of the E2 gene. We 
were also not able to identify any disturbances or changes in the secondary structure 
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 of RNA of HCV strains containing additional codons at the E1/E2 junction. Thus, the 
question of the mechanism of appearance of these extra codons remains 
unanswered and requires further studies. 
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5 Conclusion 
The current study deals with several important aspects of HCV research, including 
evolution of the envelope proteins and dynamic of the humoral immune response 
during the long term virus persistence. The essential feature of the project was the 
use of a special group of patients - women infected with the same HCV strain (AD78) 
by a contaminated anti-D globulin in a single-source outbreak. 
This unique cohort of patients infected with the same virus strain allowed the 
minimization of factors, including route of transmission, size of inoculum, duration of 
infection, age and sex of infected individuals, playing a significant role in evolution of 
the virus during the chronic infection. Nevertheless, even under these dramatic 
reduction of factors affecting intrapatient viral evolution, the established parameters, 
such as a rate of selective pressure, as well as a pattern of mutations in the E1/E2 
region, differed markedly between AD-patients. Analysis of the rate and character of 
nucleotide and amino acid substitutions in the E1/E2 region revealed no evidence for 
a strong positive selection, while a high frequency of reverse mutations to a 
consensus HCV 1b sequence was observed, indicating a critical role of 
functional/structural constrains in evolution of envelope proteins. The obtained data 
allowed to formulate an unequivocal conclusion that HCV envelope proteins evolution 
is a patient-specific phenomenon, and that purifying (negative) selection is the major 
force acting on HCV populations in chronic infection.  
Analysis of the character and localization of a.a. substitutions in envelope sequences 
of AD78 isolates obtained from AD-patients at different time points of chronic 
infection have shown that a significant part of mutations occurred in the HVRI, 
suggesting a possibilty of emergence of HCV variants escaping neutralization 
mediated by anti-HVRI antibodies. A significant number of mutations was also 
localized in known human mAbs targeted sites and, especially often, in  
CD-81-binding sites or, in other words, in the functionally relevant domains of the 
protein. These data indicated that in most AD-patients the whole ectodomain of  
E2 protein and not only the HVRI remains under evident selective pressure during 
the long term chronic infection. 
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 The other aim of the current study was the analysis of the dynamic of the  
HCV-specific humoral immune response in long term chronic patients. Application of 
the HCVpp system allowed detecting relatively high titres of cross-reacting and 
cross-neutralizing antibodies in sera of AD-patients; however, no evidence of 
immune escape during HCV persistence was registered. These experiments 
provided no evidence that humoral immune response lags behind the changes in 
envelope sequences of the virus circulating in the host at a given time point. In other 
words, our data indicated that the postulated mechanism of escape from  
antibody-mediated neutralization is not operative in all chronic patients. The results of 
the current study suggested, however, that the absence of escape from neutralization 
of virions transmitted via cell-free route does not mean that another mechanism of 
immune escape, namely, the escape from anti-HVRI antibodies, which very efficiently 
neutralize a virus transmitted by a cell-to-cell route, is not operative and does not 
contribute to HCV persistence. 
Finally, a new interesting structural feature of envelope sequences of some HCV 
strains belonging to different subtypes and genotypes - presence of additional  
1 to 4 a.a. residues at the N-terminus of the E2 protein - was studied using a set of 
hymeric E1/E2 plasmids, in which the additional a.a. residues were swapped with a 
number of natural or artificial a.a. stretches. These experiments have demonstrated 
that the presence of additional a.a. track may result in a significant increase of 
pseudoparticles infectivity suggesting that the viruses bearing E2 proteins with 
modified N-terminus might also posess unique biological properties in vivo. 
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a.a.     Amino Acid 
Ab      Antibody 
ARFP     Alternative frame protein 
APC     Antigen-presenting cell 
BCR      B-cell receptor 
BSA     Bovine serum albumin 
bp     Base-pair 
°C      Degree in Celsius 
CD      Cluster of differentiation 
Con1     Replicon construct 
CTL     Cytotoxic T lymphocyte 
g      Micrograms 
l      Microlitre 
CLDN1    Claudin-1 
CLP(s)     Capsid-like particle(s) 
C-terminus     Carboxy-terminus 
DC     Dendritic cells 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DMSO    Dimethyl sulfoxide 
DNA     Desoxyribonucleic acid 
dNTP     Desoxynucleotidetriphosphate 
dsRNA    Double-stranded RNA 
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 E1     Envelope 1 
E2     Envelope 2 
E.coli      Escherichia coli 
EDTA     Ethylenediaminetetraacetic acid 
ELISA     Enzyme Linked Immuno Sorbent Assay 
ER     Endoplasmatic Reticulum 
FACS     Fluorescence Activated Cell Sorting 
FBS     Fetal bovine serum 
FCS      Fetal calf serum 
Fig     Figure   
F-Protein    Frame shift protein 
g      Grams 
Gt      Genotype 
h      Hours 
HBV      Hepatitis B virus 
HCC     Hepatocellular carcinoma 
HCV      Hepatitis C virus 
HCVcc    Hepatitis C virus cell culture 
HCVpp     Hepatitis C virus pseudoparticle 
HDL     high-density lipoproteins 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV     Human immonudefiency virus 
HLA      Human leukocyte antigen 
HRP      Horseradish-Peroxidase 
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 HVRI      Hypervariable region 1 
IFN     Interferon 
Ig     Immunoglobulin 
Ig G     Immunoglobulin G 
IL     Interleukin 
IRES      Internal Ribosome Entry Site 
kD      Kilodalton 
LB      Lurian Broth 
LEL     long extracellular loop 
mAb(s)    monoclonal antibody (ies) 
mg      Milligrams 
min      Minutes 
ml      Millilitre 
mM      Millimolar 
MLV     murine leukemia virus 
mRNA    messenger RNA 
Mw     molecular weight 
nAb     neutralizing antibody 
NK     natural killer cells 
NKT     natural killer T cells 
nm      Nanometers 
NS     non-structural protein  
nt     nucleotide 
N-terminus     Amino-terminus 
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 NTPase    Nucleoside triphosphate hydrolase 
OD      Optical density 
ORF     Open reading frame 
PAGE     Polyacrylamide-Gelelektrophoresis 
PAMPs    Pathogen-associated molecular patterns 
PBS      Phosphate buffered saline 
PCR      Polymerase chain reaction 
PD-1     Programmed Death 1 
PD-L     Programmed Death Ligand 
p.i.     post infection 
RBS      Ribosome Binding Site 
RLU     Relative-Light-Units 
RNA      Ribonucleic acid 
rpm      Revolutions per minute 
Rt      Room temperature 
RT     Reverse trancriptase 
SDS      Sodium dodecylsulfate 
sE2     soluble envelope 2 
Sec     second 
siRNA     small inteferring RNA 
SR-BI     Scavenger receptor class B member 1 
TTBS      Tris tween buffered saline 
U      Units 
UTR       Untranslating region 
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 UV-light     Ultra violet light 
V      Volt 
VLDL     very low density lipids 
VSV     Vesicular stomatitis virus 
WB      Western blot 
WHO       World Health Organization 
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8.1 Vectorcards 
 
pCR4-AD78-E1E2: The plasmid contains the pUC origin, an Ampicillin resistant Promotor (AmpR-
Promotor), the Ampicillin resistant gene (Ampicillin-R), the Kanamycin resistant gene (Kanamycin-
R)as well as the Kanamycin resistant- Promotor (KanR-Promotor) into which the AD78 derived E1/E2 
sequences were inserted using the EcoRV restriction sites. The hyper variable region as described in 
(Fig.3.15.) was exchanged by SalI and PsiI restriction. 
 
 
pHCMV-IRES-AD78-E1E2: The expressing plasmid contains the Ampicillin resistant gene 
(ApR), the CMV promoter, an Intron, the IRES sequence of EMC. E1 starts at bp 2306-2880 and E2 
starts at bp 2881-3979. The restriction sites SalI (768 bp) and PsiI (1153, 6809) were removed by 
SDM but are mentioned here for better understanding. The polyA signal matures the process of 
mRNA translation.  
	ABCDE	F	

E2
E1
Intron
ATG - start of translation
ApR
AD78 additional aa trackpolyA signal
P CMV
IRES sequence of EMCV
	A
B	A
CDBEB	A
CDF	A
	EEA
	BF	A
		FA
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 8.2 Aligment of E1 a.a. sequences of HCV AD78 Gl8 and infected patients 
                     10        20        30        40        50        60        70              
            ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
G_k01       YEVRNVSGVYHVTNDCSNSSIVYETADMIMHTPGCVPCVREDNSSRCWVALTPTLAARNGSVPTTAIRRH  
G_k02       ......................................................................  
G_k03       ......................................................................  
G_k04       ......................................................................  
G_k05       ............................................P.........................  
G_k06       ..................................R...................................  
G_k07       ......................................................................  
G_k08       ......................................................................  
G_k09       ......................................................H...............  
G_k10       ......................................................................  
G_k11       ......................................................................  
G_k12       ......................................................................  
G_k13       ...............R.............V........................................  
G_k14       ......................................................................  
G_k15       ......................................................................  
G8_k27      ......................................................................  
G8_k28      ......................................................................  
G8_k29      ......................................................................  
G_K16       ..........Q................................................S.....T....  
G_K17       ..........Q................................................S.....T....  
G_K18       ..........Q................................................S.....T....  
G_K19       ..........Q.....................L..........................S.....T....  
G_K20       ..................T..................Y.....................S.....T....  
G_K21       ..........Q................................................S.....T....  
G_K22       ..........Q................................................S.....T....  
G_K23       ..........Q................................................S.....T....  
G_K24       ..........Q................................................S.....T....  
G_K25       ..................T.................LY................................  
G_K26       ..........Q................................................S.....T....  
T89E1_1     ..........Q..............................N.................S.....T....  
T89E1_6     ..........Q..............................N.................S.....T....  
T89E1_9     ..........Q..............................N.................S.....T....  
T89E1_11    ..........Q..............................N.................S.....T....  
T89E1_17    ..........Q..............................N.................S.....T....  
T95E1_2     ..........Q............................L.N.................S.....T....  
T95E1_5     ..........Q............................L.N.................S.....T....  
T95E1_11    ..........Q..............................N.F...............S.....T....  
T95E1_14    ..........Q.............................GS.................S.....T....  
T95E1_17    ..........Q............................L.N.................S.....T....  
T98E1_1     ..........Q............................L.N.................S.....T....  
T98E1_2     ..........Q............................L.N.....R...........S.....T....  
T98E1_3     ..........Q............................L.N.................S.....T....  
T98E1_4     ..........Q............................L.N.................S.....T....  
T98E1_5     ..........Q............................L.N.................S.....T....  
T98E1_6     ..........Q............................L.N.................S.....T....  
T98E1_7     ..........Q............................L.N.................S.....T....  
T98E1_13    ..........Q............................L.N.................S.....T....  
T06E1_2     ..........Q...........F................L.N.................S....AT....  
T06E1_3     ..........Q...........F................L.N.................S....AT....  
T06E1_7     ..........Q...........F................L.N.................S....AT....  
T06E1_9     ..........Q...........F................L.N.................S....AT....  
T06E1_10    ..........Q...........F................L.N.................S....AT....  
H89E1_10    .........................................S.F..........................  
H89E1_12    .........................................S.F..........................  
H89E1_13    .........................................S.F..........................  
H89E1_16    .........................................S.F..........................  
H89E1_24    .........................................S.F..........................  
H94E1_2     .........................................S.F..........................  
H94E1_3     .........................................S.F..........................  
H94E1_6     .........................................S.FP.........................  
H94E1_9     .........................................S.F..........................  
H94E1_10    .........................................S.FP.........................  
H98E1_4     .........................................S.L.....E....................  
H98E1_5     H........................................S.F..........................  
H98E1_6     H........................................S.F..........................  
H98E1_9     .........................................S.L..........................  
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 H98E1_10    .........................................S.L.....E...................R  
H98E1_15    .........................................S.F.....E...............E...R  
H98E1_16    .........................................S.L.....E....................  
H06E1_2     .........................................S.F..........................  
H06E1_21    .........................................S.F................G.........  
H06E1_36    .....................M...........R.......S.F..........................  
H06E1_41    .........................................S.F.....E....................  
H06E1_42    .........................................S.F..........................  
H06E1_49    .........................................S.F..........................  
M95E1_4     .....TTEA.Y.............A................A...................I........  
M95E1_5     ...C.ATEA.Y....G....T....................A...................I........  
M95E1_6     .....TTEA.Y........I....A................G...................I........  
M95E1_10    .....TTEA.Y.............A................G...................I........  
M95E1_8     .....TTEA.Y...G....I....A................G...................I........  
B98E1_3     ............................V.........................................  
B98E1_5     ......................................................................  
B98E1_7     .................................................................T....  
B98E1_12    ......................................................................  
B98E1_33    ......................................................................  
B98E1_34    .....................................R................................  
B98E1_35    ......................................................................  
N98E1_1     .........................................G............V....S.....T....  
N98E1_4     ..........Q............................Q.G............V....S.....T....  
N98E1_10    .........................................G............V....S.....T....  
N98E1_19    .....................M...................G............V....S.....T....  
N98E1_20    ..........Q............................Q.G............V....S.....T....  
X98E1_3     ...........................L.............G..................R...A.....  
X98E1_4     .......E.................T.L.............G..................T...A.....  
X98E1_6     .........................T.L.............G..................R...A.....  
X98E1_7     ..E......................T.L...I.........G..................P...A....N  
X98E1_13    ..E.............................................................A.....  
J98E1_6     ...........................................................S........P.  
J98E1_9     ...........................................................S..........  
J98E1_10    ......................................................................  
J98E1_13    ....S.................................................................  
J98E1_19    .......E...................................................R..........  
J98E1_21    ...........................................................R..........  
Y98E1_2     ....D.............T......................N..............G.............  
Y98E1_3     ..................T......................N..............G.............  
Y98E1_4     ..................T......................N..............G.............  
Y98E1_6     ..................T......................N..............G.............  
Y98E1_8     ..................T......................N..............G.............  
Y98E1_11    ..................T......................N..............G.............  
Z98E1_1     ..........Q......D.......S.................................S.....T....  
Z98E1_2     ..........Q..............S.................................S.....T....  
Z98E1_3     ..........Q..............S.........M.......................S.....T....  
Z98E1_4     ..........Q..............S.................................S.....T....  
 
                     80        90       100       110       120       130       140         
            ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
G_k01       VDLLVGAAAFCSAMYVGDLCGSVFLVSQLFTLSPRRHETVQECNCLIYPGHVTGHRMAWDMMMNWSPTTA  
G_k02       ......................................................................  
G_k03       ......................................................................  
G_k04       ......................................................................  
G_k05       .............................................S........................  
G_k06       ......................................................................  
G_k07       ......................................................................  
G_k08       .............................................S........................  
G_k09       .....................................G.........C......................  
G_k10       .............................................S........................  
G_k11       .............................................S........................  
G_k12       .............................................S........................  
G_k13       ......................................................................  
G_k14       .............................................S........................  
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